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Cardamonin inhibits signal
transducer and activator of
transcription 3 activation by directly
binding SH2 to its domain in
prostate cancer cells
Jingwen Zhang1, Sakshi Sikka2, Kodappully
Sivaraman Siveen2, Jong Hyun Lee3, Alan Prem
Kumar2, Kwang Seok Ahn3 and Gautam Sethi2
1National University of Singapore, Singapore
2Department of Pharmacology, Yong Loo Lin
school of Medicne, National University of
Singapore, Singapore
3College of Korean Medicine, Kyung Hee
University
Signal transducer and activator of tran-
scription 3 (STAT3) is persistently active
in a wide variety of malignancies including
prostate cancer(PCa) and plays a critical
role in the proliferation, angiogenesis and
metastasis of tumor. Targeting deregulated
STAT3 activation by employing novel
pharmacological agents can be considered
as a reasonable strategy for PCa therapy.
In the present study, we observed that car-
damonin (CD), isolated from the fruit
Amomum subulatum, can function as a
potent anti-proliferative and pro-apoptotic
agent against PCa cells through negatively
regulating STAT3. CD suppressed STAT3
phosphorylation as well as its nuclear
translocation and DNA binding ability in
PCa cells. It also decreased the protein
expression of STAT3 downstream target
gene products such as BcL-2, VEGF, XIAP
and MMP-9. Computational modeling
showed that CD could bind directly to the
SH2 domain of STAT3 and also inhibit its
dimerization. This chalcone was also noted
to significantly suppress the migratory/
invasive potential of PCa cells. Overall, our
data indicates that the potential application
of CD as a STAT3 blocker might form the
basis of novel therapy for PCa patients.
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Depletion of L1CAM by siRNA
inhibits prostatic cancer cell
invasion in vitro
Mohammed Al Kerithy and Fawzi Bokhari
Armed Forces Hospitals General
Administration – Taif Region, Saudi Arabia
Although cancers have been heavily trea-
ted with surgery, chemotherapy, and radi-
ation therapy, the side effects, specificity,
and complications of these treatment
options are uncountable. Of these neoplas-
tic disorders is prostate cancer. It is a dev-
astating malignancy worldwide and
present demanding diagnostic and man-
agement to the clinicians. Despite the
advancement of prostatic cancer diagnostic
technologies, current treatment options
remain defective. Through in vitro investi-
gations, the depletion of L1 cell adhesion
molecule (L1CAM) by specifically
designed siRNA has helped the reduction
of metastatic invasion of cells. This obser-
vation was also tested positive where the
inhibition of L1CAM inhibited colony for-
mation. These results initiate potentials to
develop targeted therapy for prostatic can-
cer using siRNA targeting L1CAM.
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Comparison of patient-reported
quality-of-life and complications in
men with prostate cancer, between
two modes of administration
Rasa Ruseckaite1, Fanny Sampurno1, Jeremy
Millar2 and Sue Evans1
1Monash University, Melbourne, Australia
2William Buckland Radiation Oncology
Service, Alfred Health, Melbourne, Australia
Objectives: To (i) assess the level of con-
sistency between the quality-of-life scores
of men with prostate cancer for urinary/
bowel/sexual bother, collected via tele-
phone versus self-administered survey; and
(ii) determine factors associated with vari-
ation in level of agreement.
Methods: Cohen’s Kappa coefficients were
calculated to investigate test-retest reliabil-
ity across modes of administration. Logis-
tic regression models explored patients’
characteristics associated with the magni-
tude of the problem.
Results: Data of 168 men were analyzed.
Kappa-linear model showed the greatest
concordance for bowel bother (90%) for
both modes of administration. Age, disease
risk and treatment type determined a good
agreement between administration modali-
ties, Kappa varying between 0.64 and 0.73,
v2: 8.18, p = 0.042.
Conclusions: A health-related outcome
initiative has been recently established to
combine data from two clinical registries,
where one collects telephone-administered
quality-of-life data and the other collects
self-administered data. Methods and
results of this study will provide a good
basis for future quality-of-life studies to be
conducted using the pooled registry data.
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A descriptive analysis of diagnostic
and treatment characteristics of
men with prostate cancer from a
regional area with high mortality
rates in Victoria, Australia
Rasa Ruseckaite1, Fanny Sampurno1, Jeremy
Millar2, Mark Frydenberg3 and Sue Evans1
1Monash University, Melbourne, Australia
2William Buckland Radiation Oncology
Service, Alfred Health, Melbourne, Australia
3Department of Surgery, Monash Medical
Centre, Melbourne, Australia
Objectives: To describe patterns-of-care
for men diagnosed with prostate cancer in
a specific Victorian region, between 2008
and 2013, and compare the outcomes with
other Victorian regions.
Methods: Series of 7,204 men were
included in the analysis. Descriptive analy-
ses were used to compare risk factors,
treatment type and time-taken-to-treat-
ment in regional and metropolitan regions.
Results: Compared with men living in
other Victorian regions, men diagnosed
with prostate cancer in the study region
were more likely to be diagnosed at older
age with more advanced disease, and inci-
dentally rather than through case-finding
PSA blood tests. In risk groups where
immediate treatment is often indicated,
they were less likely to have the treatment.
They were more likely to have a longer
time from diagnosis to active treatment.
Conclusion: Multiple factors explain the
higher mortality rate post-diagnosis in the
study regional area. This range of explana-
tory factors, occurring at multiple points
along the pathway of diagnosis and detec-
tion, suggests that interventions to
improve outcomes for prostate cancer in
regional areas such as this need to be sys-
tematic.
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Epithelial cell adhesion molecule
(EpCAM) is associated with prostate
cancer chemo-/radio-resistance in
cell lines in vitro and in animal
models in vivo
Jie Ni1, Paul Cozzi2, Jingli Hao3, Julia Beretov3,
Lei Chang3, Junli Deng3, Wei Duan4, Peter
Graham3, Joseph Bucci3 and Yong Li3
1The University of New South Wales, Australia
2St George Hospital, Australia
3UNSW & St George Hospital, Australia
4Deakin University, Australia
Prostate cancer (CaP) is the most common
cancer in men in western world. Our
recent studies indicate EpCAM is a CaP
stem cell-like marker with overexpression
in CaP cell lines and human tissues, and
associated with invasion and metastasis.
However, the role of EpCAM in CaP ther-
apeutic resistance is still uncertain. We
aimed to investigate the role of EpCAM in
CaP chemo-/radio-resistance as well as
underlying pathways in vitro and in vivo
to find a potential therapeutic target. Ep-
CAM was knocked down (KD) in its over-
expression cells PC-3, DU145 and LNCaP-
C4-2B using shRNA. EpCAM-KD and
control (scr-KD) cells were examined for
invasion, colony formation, proliferation,
sphere formation, chemo-/radio-sensitivity
assays and PI3K/Akt/mTOR pathway pro-
teins by different techniques. Subcutaneous
(s.c) and orthotopic CaP animal xenograft
models were established using PC-3-Ep-
CAM-KD and PC-3-scr-KD cells, to assess
the tumour growth, chemo-/radio-sensitiv-
ity, the changes of PI3K/Akt/mTOR path-
way proteins and apoptosis pathway
proteins by immunohistochemistry. Three
EpCAM-KD CaP cells showed an obvious
decrease in invasion, colony formation,
proliferation, sphere formation, and a sig-
nificant increase in chemo-/radio-sensitiv-
ity, compared to the control cells,
respectively. They also demonstrated sig-
nificant down-regulation of PI3K/Akt/
mTOR pathway proteins in vitro. In vivo,
both s.c and orthotopic PC-3-EpCAM-KD
xenografts displayed reduced tumour
growth after docetaxel or radiation treat-
ment compared to control xenografts
(p < 0.05). We also found obvious down-
regulation of PI3K/Akt/mTOR pathway
proteins and greatly increased apoptotic
proteins in EpCAM-KD CaP xenografts
after docetaxel or radiation treatment.
Over-expression of EpCAM is associated
with CaP progression, and chemo-/radio-
resistance via PI3K/Akt/mTOR signalling
pathway. Targeting EpCAM combined
with docetaxel or radiation is promising
for the treatment of CaP, especially for
castrate-resistant prostate cancer.
035
Reactive stroma
componentCOL6A1 is upregulated
in castration-resistant prostate
cancer and promotes tumor growth
Yiping Zhu, Fangning Wan, Yijun Shen and
Dingwei Ye
Fudan University Shanghai Cancer Center
Objective: Castration-resistant prostate
cancer (CRPC) remains the most critical
challenge in the clinical management of
prostate cancer (PCa).Reactive stromal
changes in PCa are likely involved in the
emergence of CRPC. In the present study,
we aim to explore the functional role of a
novel oncogene termed COL6A1 which
was upregulated in the reactive stroma of
CRPC.
Methods: We established an androgen-
independent LNCaP (LNCaP-AI) cell line
in steroid-reduced (SR) medium within
2 months. We examined COL6A1 expres-
sion with western blot during the LNCaP-
AI induction, and studied the function of
COL6A1 in vitro and in vivo. Immunohis-
tochemical staining of COL6A1 was per-
formed in ten pairs of androgen-sensitive
PCa and CRPC samples.
Results: We demonstrated that COL6A1
expression was markedly increased in
LNCaP-AI cells and CRPC tissues com-
pared with LNCaP cells and paired andro-
gen-sensitive PCa specimens. In vitro,
COL6A1 knockdown resulted in G1-S cell
cycle arrest and descended vitality. Over-
expression of COL6A1 was associated with
accelerated S phase entry and elevated
vitality in prostate cancer cells. COL6A1
also promoted tumorigenesis of LNCaP
cells in vivo.
Conclusion: Taken together, these data
suggest an important role of COL6A1 in
the molecular etiology of castration-resis-
tant prostate cancer, and support the
potential use of COL6A1 in CRPC
therapy.
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Heberprovac, a therapeutic GnRH
based vaccine to treat advanced
prostate cancer
Jesus Arturo Junco Barranco1, Franklin
Fuentes1, Ranfis Rodrıguez2, Lesvia Calzada1,
Idania Baladr on1, Eulogio Pimentel1, Roberto
Basulto1, Osvaldo Reyes1, Hilda Garay1, Maria
D Castro Santana1, Niurka Arteaga1, Rolando
Mor an1, A Rodrıguez3 and Gerardo Guillen1
1Center for Genetic Engineering and
Biotechnology, Cuba
2Hospital Oncol ogico Marie Curie de
Camaguey, Cuba
3Medical University of Camaguey, Cuba
GnRH-based vaccines represent a promis-
ing anti-hormonal treatment alternative
in prostate cancer, because they can
reduce serum testosterone to castrating
levels, avoid the “hot flushes” produced
by GnRH analogues and can be adminis-
tered in acute and complicated forms of
prostate cancer. The present study
assesses the application of Heberprovac, a
GnRH based vaccine candidate for
patients suffering from advanced prostate
cancer.
The main objective of the clinical trial was
to evaluate the safety and efficacy of this
vaccine candidate in 4 levels of dosage.
To this aim, 56 patients affected by
advanced prostate cancer diagnosed by
biopsy, were included. As result, after the
first immunizations, the patients exhibited
anti GnRH antibodies and in turn, testos-
terone levels reduction. In concordance
with the hormonal and immunological
response, the patients exhibit a decrease of
both; the number of obstructive symptoms
as well as the severity of them. There was
also a normalization of the prostatic
specific antigen (PSA) in the 80% of the
patients after they finished the last
immunization and the clinical evaluation
demonstrated the significant reduction of
the primary tumor from grades III/IV to
I/II in all the patients that respond
biochemically.
Regarding the safety, majority of adverse
effects of the vaccine were those expected
according to the mechanism of action of
the vaccine through the reduction of
testosterone levels. No severe adverse
events were found in any of the patients.
We conclude that the vaccine proved to be
safe and effective in the 4 dose levels.
© 2015 The Authors
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Inhibition of ASCT2-mediated
glutamine uptake blocks prostate
cancer growth
Qian (Kevin) Wang1, Rae-Anne Hardie1,
Andrew J Hoy2, Michelle van Geldermalsen1,
Dadi Gao1, Ladan Fazli3, Martin C Sadowski4,
Seher Balaban2, Mark Schreuder2, Michelle
van Geldermalsen1, Nicholas J Otte1, Melanie
L Lehman4, Martin Gleave3, Colleen C
Nelson4, Charles G Bailey1, William Ritchie1,
John EJ Rasko1 and Jeff Holst1
1Centenary Institute, University of Sydney,
Australia
2University of Sydney, Australia
3University of British Columbia, Canada
4Queensland University of Technology,
Australia
Background: Alanine-serine-cysteine
transporter-2 (ASCT2; SLC1A5) mediates
cellular uptake of amino acids including
glutamine. Glutamine is conditionally
essential in cancer cells, being utilized as a
carbon and nitrogen source for macromol-
ecule production, for anaplerotic reactions
fueling the tricarboxylic acid (TCA) cycle
as well as being required for signaling
through the mTORC1 pathway. In this
study, we investigate the role of glutamine
transporter ASCT2 in prostate cancer.
Methods: We examined ASCT2 mRNA
and protein expression in a TCGA dataset
and human prostate cancer tissue micro-
array. We examined the role of ASCT2-
mediated glutamine uptake on gene
expression, downstream metabolic path-
ways, cell cycle, mTORC1 pathway and
cell growth using inhibitors and shRNA in
LNCaP and PC-3 prostate cancer cell
lines, as well as a PC-3 xenograft mouse
model.
Results: In this study, we demonstrate
ASCT2 is highly expressed in prostate can-
cer patient samples. We show that chemi-
cal or shRNA-mediated inhibition of
ASCT2 function in vitro decreases gluta-
mine uptake, cell cycle progression
through E2F transcription factors,
mTORC1 pathway activation and cell
growth. Chemical inhibition also reduces
basal oxygen consumption and fatty acid
synthesis, showing that downstream meta-
bolic function is reliant on ASCT2-medi-
ated glutamine uptake. Furthermore,
shRNA knockdown of ASCT2 in PC-3 cell
xenografts significantly inhibits tumor
growth and metastasis in vivo, associated
with the down-regulation of E2F cell cycle
pathway proteins.
Conclusion: ASCT2-mediated glutamine
uptake is essential for multiple pathways
regulating cell cycle and cell growth, and
is therefore a putative therapeutic target in
prostate cancer.
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Multimodality imaging of a novel
spontaneous prostate cancer liver
metastasis model
Stefan J Roobol1, Hanneke AA van Zoggel2,
Corrina MA de Ridder2, Sander AH Hoeben2,
C Yin2, L Versluis2, Joost C Haeck3, R Yanto
Ridwan4 and Wytske M van Weerden2
1Erasmus MC, The Netherlands
2Department of Urology, Erasmus MC, The
Netherlands
3Department of Radiology, Erasmus MC, The
Netherlands
4Department of Genetics, Erasmus MC, The
Netherlands
Prostate Cancer (PCa) preferentially
spreads to bone with additional metastasis
to lung and liver in a small subset of
patients.
Understanding the determining factors of
this metastatic pattern and to elucidate the
involved pathways and interplay between
epithelial and stromal niches we developed
a patient-derived xenograft model that
shows spontaneous metastatic spread to
relevant organs.
We generated a new liver metastasis model
PCL339_M21_L by subcutaneous inocula-
tion of PCL339 3D cell cultures transfect-
ed with luc2-GFP fused protein (M21) in
mice. Mice with established subcutaneous
tumors underwent tumorectomy (700–
1,000 mm3) after which the animals were
monitored weekly using MRI, microCT
and IVIS imaging to monitor metastatic
development. At sacrifice, liver and lucifer-
ase-positive organs were stored for RNA
isolation and qPCR and for immunohisto-
chemistry (IHC).
Luciferase-positive signals in liver were
detected by IVIS as early as 7 days after
tumorectomy, while MRI showed the first
visible lesions at 21 days and microCT
imaging was able to detect lesions at
28 days. 3D reconstructed microCT
images and MRI-detected lesions con-
firmed the signals and location as seen by
IVIS. Presence of (micro)metastatic lesions
in liver, lung and other organs was con-
firmed by qPCR and IHC for luc2 and
GFP respectively.
A new PCa liver metastasis model
PCL339_M21_L was generated. We dem-
onstrated the feasibility of non-invasive
imaging techniques to follow metastatic
spread and outgrowth. This model is a
useful tool to study the biology of meta-
static outgrowth in the liver and to moni-
tor responses to anti-cancer therapies.
055
The mutational landscape of the
mitochondrial genome in prostate
cancer
Anton Kalsbeek1, Eva Chan1, Ruth Lyons1,
Desiree Petersen1, Anne-Maree Haynes1,
Sarita Tiwari1, Ruta Gupta2, James Kench2,
Philip Stricker3 and Vanessa Hayes1
1Garvan Institute for Medical Research,
Sydney, Australia
2Royal Prince Alfred Hospital, Sydney,
Australia
3St Vincents Private Hospital, Sydney, Australia
Objective: To explore the clinical signifi-
cance and biological implications of
acquired mitochondrial DNA (mtDNA)
mutations driving high-risk prostate can-
cer (PCa).
Methods: We microdissected PCa from
frozen biopsies taken after radical prosta-
tectomy from 38 patients, 33 with high
(8 + ) and 5 with low (6) Gleason grades.
Mean follow-up was 59 months. Deep
sequencing was performed to interrogate
the mutational landscape of the mitochon-
drial genome of PCa tumour compared to
the matched blood samples.
Results: Mitochondrial genomes were
sequenced to an average of 3,000 times cov-
erage with a tumour purity of 60–99%. We
identified 39 novel (88.6%) and 5 previously
known PCa somatic mtDNA mutation sites
in 21 patients (55.3%), three mutations
occurring in two patients. Mutational fre-
quencies ranged from 15% to 98%, repre-
senting both heteroplasmic (the presence of
more than one mtDNA population in a
cell) and homoplasmic (a uniform collec-
tion of mtDNA) states. Somatic mutations
occurred in 2 (40%) of low Gleason grades
and in 19 (58%) of high Gleason grades.
Conclusions: We confirmed that PCa is
characterized by changes in the mitochon-
drial genome. This pilot study could result
in a better characterisation of low and
high grade prostate cancer; clinical signifi-
cance of the mitochondrial mutations has
yet to be determined by including more
samples in a disease association analysis.
32 © 2015 The Authors
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Enrichment and propagation of
circulating tumour cells in men with
hormone na€ıve metastatic prostate
cancer
Handoo Rhee, Jennifer Gunter, Lidija
Jovanovic, Elizabeth D Williams, Brett Hollier,
Ian Vela and Colleen C Nelson
Australian Prostate Cancer Research Centre –
Queensland, Institute of Health and
Biomedical Innovation, Queensland University
of Technology, Princess Alexandra Hospital,
Translational Research Institute, Brisbane,
Australia
Objective: To determine the suitability of
circulating tumour cells (CTCs) as prog-
nosticating indicator and biomarker for
delivery of precision medicine
Methods: Patients were recruited and
screened (n = 20) as a part of ADMET
(Androgen Deprivation Therapy and
Adjuvant Metformin) trial. 5 mL of whole
blood was collected from patients for CTC
enrichment, enumeration and propagation.
Enrichment was performed using CD45
negative selection kit (RosetteSepTM).
CTCs were identified using immunofluo-
rescence imaging with antibodies against
prostate specific antigen, cytokeratin,
CD45 and nucleus. Cells were propagated
in customized stem cell solution with hyp-
oxic conditions.
Results: At screening, 18 of 20 patients
demonstrated circulating tumour cells with
the mean number of 574 (range 1–1,763,
613). In all of the enriched samples, cells
could be propagated temporarily with the
peak population being reached at
3.5 weeks. Cells were cultured in both 2D
and 3D conditions and temporary orga-
noids could be developed from 5 of 18
patients. Polymerase chain reaction and
immunofluorescence imaging at 4 weeks
after culturing demonstrated characteristics
consistent with prostate cancer cells.
Conclusions: Circulating tumour cell tech-
nology remains a viable option as a means
of providing biomarker information and
tumour activity indicator in delivering pre-
cision medicine. Firstly, enumeration can
be used to help determine the response to
a treatment. Secondly, temporary culture
and progression into development of orga-
noids may be used to allow for down-
stream analysis and therapeutic decision.
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Investigating the role of a potential
angiogenic target, YKL40, for the
treatment of metastatic prostate
cancer
Varinder Jeet, Anja Rockstroh, Melanie
Lehman and Colleen C Nelson
Australian Prostate Cancer Research Centre –
Queensland, Institute of Health and
Biomedical Innovation, Queensland University
of Technology, Princess Alexandra Hospital,
Translational Research Institute, Brisbane,
Australia
Angiogenesis plays a fundamental role in
promoting tumour growth and hence anti-
angiogenesis therapy has provided a prom-
ising approach for treating patients with
metastatic castration resistant prostate
cancer (CRPC) disease. Despite clinical
benefits in some cancers, the results of
anti-angiogenic (mainly anti-VEGF) ther-
apy in prostate cancer (PCa) are relatively
modest, possibly due to alternative escape
routes employed by tumour cells. YKL40
has been identified as a tumour angiogenic
factor and a potent inducer of carcinogen-
esis in glioblastoma, breast, and colon can-
cers. We have recently shown for the first
time in PCa that YKL40 expression
increases with progression to CRPC phe-
notype in PCa cell lines and clinical sam-
ples. We also show that YKL40 affects cell
invasion, migration, and clonogenicity of
PCa cells. However, the therapeutic value
of targeting YKL40 and its role in tumori-
genic pathways remains unknown in PCa.
Objective: We aim to understand the role
YKL40 plays in influencing the progres-
sion of metastatic prostate cancer and also
to elucidate its potential as a novel thera-
peutic target.
Methods: Effect of YKL40 on the expres-
sion profile of angiogenic and proinflam-
matory targets was analysed by
quantitative PCR and immunoblotting.
Gene expression microarrays were per-
formed to delineate the network biology of
YKL40.
Results: Our preliminary results show that
YKL40 significantly increased the expres-
sion of vascular endothelial growth factor
(VEGF) and interleukin 6 (IL6) both at
the gene and protein levels. Gene expres-
sion microarray analysis is underway to
further explore the relationship of YKL40
with other molecules in the angiogenesis
cascade.
Conclusion: The novel findings from this
study may indicate the potential of YKL40
as an anti-angiogenic target for the treat-
ment of PCa as well as a contributor to
key tumorigenic pathways.
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Combination of LBH589 and
radiotherapy overcomes
radioresistance in radioresistant
prostate cancer cells in vitro and
animal models in vivo
Jingli Hao1, Peter Graham1, Lei Chang2, Jie
Ni2, Julia Beretov3, Junli Deng2, Joseph Bucci1,
Paul Cozzi4 and Yong Li1
1Cancer Care Centre, St George Hospital,
Australia
2St George and Sutherland Clinical School,
Faculty of Medicine, University of New South
Wales, Australia
3SEALS, Anatomical Pathology, St George
Hospital, Australia
4Department of Surgery, St George Hospital,
Australia
Background: Radioresistance is a major
problem in prostate cancer (CaP) radio-
therapy (RT). Increased DNA acetylation
is a mechanism leading to radiation
caused cell death. Histone deacetylase
(HDAC) reverses DNA acetylation, regu-
lates chromatin structure and inhibits
radiation caused apoptosis.
Aims: We aimed to investigate whether
LBH589, a pan-HDAC inhibitor, can be
used to achieve a sensitizing effect on CaP
radioresistant (RR) cells and animal xeno-
grafts and to uncover the underlying
mechanisms.
Method: The optimal dose of LBH589
was determined in CaP-RR cell lines
(PC3-RR, DU145-RR, LNCaP-RR) using
MTT assay. Vehicle (VC), LBH589, RT or
LBH589 + RT were used to treat CaP-RR
cells. Survival fractions of CaP-RR cells
were examined using clonogenic assay.
Cancer stem cell (CSC), apoptosis, auto-
phage and DNA repair markers were
examined using western blot. Subcutane-
ous and orthotopic xenograft animal mod-
els were established using PC3-RR-luc
cells. The tumour growth rates were moni-
tored using Xenogen system after VC, sin-
gle and combination treatments. CSC,
apoptosis, autophage markers were exam-
ined in tumours by immunohistochemisty.
Result: Combined LBH589 and RT signif-
icantly reduced survival rates, induced
apoptosis in CaP-RR cells compared to
single LBH589, RT or VC treatments. The
tumour growth rate of LBH589 and RT
combination treated mice was significantly
© 2015 The Authors
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regressed compared to that in single and
VC treatments. The expression of CSC
obviously reduced; the expression of auto-
phage, and apoptosis markers were mark-
edly increased in CaP cells in vitro and
CaP-RR xenografts in vivo.
Conclusion: LBH589 can be used as a
radiosensitizer to amplify the effect of
radiotherapy on CaP-RR cells in vitro and
CaP-RR xenografts in vivo. The increased
cell death from combination therapy
might result from the impaired DNA
repair capability and the suppression of
CSCs, indicating this approach is a prom-
ising strategy to overcome recurrent CaP
after initial radiation therapy.
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The ghrelin receptor antisense long
non-coding RNA, GHSROS, in
prostate cancer growth and
survival
Patrick Thomas1, Carina M Walpole2,3, Penny
L Jeffery2,3, Lidija Jovanovic1, Adrian C
Herington2,3, Colleen C Nelson4, Eliza J
Whiteside2, Rakesh N Veedu5, Inge Seim2,3
and Lisa K Chopin2,3
1Australian Prostate Cancer Research Centre
– Queensland, Institute of Health and
Biomedical Innovation, Queensland University
of Technology, Princess Alexandra Hospital,
Translational Research Institute, Australia
2Ghrelin Research Group, Institute of Health
and Biomedical Innovation, Queensland
University of Technology, Translational
Research Institute, Brisbane, Australia
3Australian Prostate Cancer Research Centre
– Queensland, Institute of Health and
Biomedical, Australia
4Australian Prostate Cancer Research Centre
– Queensland, Institute of Health and
Biomedical Innovation, Queensland University
of Technology, Princess Alexandra Hospital,
Translational Research Institute, Brisbane,
Australia
5Centre for Comparative Genomics, Murdoch
University, Perth, Australia
Prostate cancer is the most commonly
diagnosed cancer in Australian males.
Long non-coding RNAs (lncRNAs) play
key regulatory roles in cancer progression,
and are potential novel therapeutic targets.
We have discovered a lncRNA which is
antisense to the growth hormone secreta-
gogue receptor (GHSR) gene, termed
GHSROS (GHSR opposite strand).
Objective: The objective of this study was
to investigate the expression and function
of GHSROS in prostate cancer.
Methods: GHSROS expression was inves-
tigated using quantitative RT-PCR in pros-
tate cancer specimens. The effects of
GHSROS on cell proliferation, migration
and cell survival were investigated using
the xCELLigence system (John Morris Sci-
entific) in DU145 and PC3 cell lines over-
expressing GHSROS. Anchorage
independent growth assays were per-
formed in vitro and tumour growth inves-
tigated in vivo using a subcutaneous
NOD/SCID mouse xenograft model. Next
generation RNA sequencing (RNAseq) was
used to identify genes differentially regu-
lated by GHSROS.
Results: The lncRNA, GHSROS, is highly
expressed in a significant subset of prostate
cancers. GHSROS stimulates cell prolifera-
tion, migration, survival, and colony growth
in prostate cancer cell lines in vitro and
increases tumour xenograft growth in vivo.
RNAseq demonstrated that genes associ-
ated with cell attachment were significantly
enriched and genes associated with metas-
tasis were upregulated by GHSROS.
Conclusions: GHSROS may have clinical
significance in prostate cancer as it is highly
expressed in a significant subset of prostate
cancers. GHSROS plays a role in cell prolif-
eration, migration, survival and tumour
growth and may provide a useful target for
the development of novel antisense thera-
pies for prostate cancer treatment.
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Multimodal hyperbranched
polymers targeting prostate specific
membrane antigen (PSMA) for
imaging of prostate cancer
Brian W-C Tse1, Adrian V Fuchs2,3, Steve S
Huang4, Warren DW Heston5, Mei-Chun Yeh1,
Andrew K Whittaker2,3, Kristofer J Thurecht2,3
and Pamela J Russell1,2
1Australian Prostate Cancer Research Centre
– Queensland, Institute of Health and
Biomedical Innovation, Queensland University
of Technology, Princess Alexandra Hospital,
Translational Research Institute Brisbane,
Australia
2Australian Institute of Bioengineering and
Nanotechnology, and Centre for Advanced
Imaging, University of Queensland, Brisbane,
Australia
3ARC Centre of Excellence in Convergent
Bio-Nano Science and Technology
4Department of Nuclear Medicine, Cleveland
Clinic, Cleveland, OH, USA
5Department of Cancer Biology, Cleveland
Clinic, Cleveland, OH, USA
Objective: Hyperbranched polymers
(HBPs) are an emerging class of biocom-
patible material that have shown some
promise in cancer imaging and therapy.
Their multiple arms allow for conjugation
with several specific functionalities. This
project compared the ability of HBPs con-
jugated with three different ligands to
image prostate cancer (PCa) in a preclini-
cal setting through binding to the extracel-
lular domain of prostate specific
membrane antigen (PSMA).
Methods: HBPs were synthesised, conju-
gated with the fluorophore Cy5 and with
one of three PSMA-targeting ligands; (i) a
peptide (HBP-pep) [1], (ii) J591 antibody
(HBP-J591) or (iii) urea glutamate (HBP-
UG). Flow cytometry and confocal micros-
copy were used in vitro to assess PSMA-
mediated internalisation of HBPs by PCa
cell lines with different PSMA expression
levels. In vivo, BALB/c nude mice bearing
subcutaneous PC3-PIP (PSMA+) and
PC3-FLU (PSMA) PCa tumours on
opposite flanks were injected intravenously
with the most promising PSMA-targeting
HBP; uptake was assessed by fluorescence
imaging.
Results: HBP-peptide and HBP-J591 were
internalised into PC3-PIP cells but not
PC3-FLU cells in a dose-dependent and
time-dependent manner. No PSMA-medi-
ated internalisation by HBP-UG or HBP-
control was evident. These trends were
confirmed in other PCa cell lines; LNCaP
and C42B (both PSMA+) and DU145
(PSMA). Intravenous injection of HBP-
peptide resulted in high accumulation of
Cy5 signal in the subcutaneous PC3-PIP
tumours but not PC3-FLU tumours
(n = 5).
Conclusions: HBP-peptide and HBP-J591
could detect PCa cells via PSMA in a pre-
clinical setting. These agents have potential
to enhance PCa detection and localization,
improving patient management.
1. Huang et al. (2014). Prostate 74:702–
713.
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PI3K/Akt signalling regulates
leucine transport in prostate cancer
Kun Zhang1, Anne Moran2,3, Jeff Holst2,3 and
Qian Wang2,3
1Centenary Institute Camperdown, NSW 2050,
Australia
2Origins of Cancer Program, Centenary
Institute, Camperdown, NSW 2050, Australia
3Sydney Medical School, University of Sydney,
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Objective: PI3K/Akt and leucine-activated
signalling are essential mediators of
mTORC1 activation, thereby regulating
protein synthesis and cell growth. In
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primary prostate cancer, leucine is pro-
vided to the cells through L-type amino
acid transporter 3 (LAT3; SLC43A1), and
LAT3 is therefore essential for mTORC1
pathway activation. PhosphoPlus database
showed that several residues of LAT3 are
phosphorylated, suggesting that LAT3 can
be regulated by signalling pathways.
Therefore, we investigate the crosstalk
between the PI3K/Akt signalling pathway
and leucine transport.
Methods: LNCaP and PC-3 human pros-
tate cancer cell lines were used for the
investigation. We conducted leucine
uptake assays and analysed Akt phosphor-
ylation, in the presence and absence of
EGF and various inhibitors of PI3K
(LY294002) and Akt (MK2206), to exam-
ine the effect on cellular uptake of leucine
and Akt pathway activation. We used the
proximity ligation assay (PLA) to explore
the in situ interaction between phosphory-
lated Akt and LAT3.
Results: Our results show that inhibition
of PI3K/Akt signalling using LY294002 or
MK2206 decreases leucine transport in
LNCaP and PC-3 prostate cancer cell
lines. EGF treatment induces PI3K/Akt
activation, and leads to a significant
increase in leucine uptake. PLA analysis
shows an increased signal in EGF-treated
LNCaP cells compared to untreated con-
trol cells, indicating that phosphorylated
Akt might interact with LAT3 to regulate
leucine transport.
Conclusion: Growth factor-activated
PI3K/Akt signalling pathway regulates leu-
cine transport through amino acid trans-
porter LAT3 in prostate cancer cell lines.
Therefore, combination of therapeutics
targeting Akt and LAT3 may provide an
increased benefit for prostate cancer
patients.
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metastatic castration resistant
prostate cancer
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2Vancouver Prostate Centre, Vancouver,
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Objective: Reactivation of the embryonic
developmental pathway, epithelial-to-mes-
enchymal transition (EMT) is associated
with prostate cancer (PCa) metastasis and
resistance to therapies. Recent evidence
has demonstrated EMT is stimulated fol-
lowing androgen deprivation therapy
(ADT). Our objective was to identify and
characterise the key mediators of ADT-
driven EMT and PCa metastasis.
Methods: IHC for transcription factor
ZEB1 protein expression was carried out
on TMAs constructed from the primary
tumours of a large cohort of clinical sam-
ples. ZEB1 staining was scored and cate-
gorised according to Gleason score,
treatment with neoadjuvant hormone ther-
apy (NHT), presence of lymph node
metastasis and CRPC. Gene expression
profiling was carried out on tumours
derived from an LNCaP progression
model. qRT-PCR and 3D MatrigelTM cul-
tures were performed after inducible ZEB1
expression or AR knockdown in LNCaP
cells.
Results: Transcriptional profiling demon-
strated ZEB1 was activated following cas-
tration in vivo. Significantly, ZEB1
expression was elevated in patients after
NHT and further increased in men with
CRPC. In vitro, ZEB1 expression increased
after ADT or AR knockdown suggesting
ZEB1 levels increase during the early
adaptive response after hormone therapy.
ZEB1 expression was also found to be
associated with increasing Gleason score
and treatment-na€ıve patients with lymph
node metastasis. An inducible model of
ZEB1 overexpression in LNCaP cells dem-
onstrated ZEB1 induced a robust EMT
concomitant with an invasive phenotype
in 3D MatrigelTM cultures.
Conclusions: In this study we show ZEB1
expression increased after ADT and corre-
lated with PCa disease progression, metas-
tasis and an invasive phenotype. These
data provides the rationale for targeting
ZEB1 providing a promising avenue for
the development of novel therapies for the
treatment of metastatic castration resistant
prostate cancer.
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Visualization of next generation
sequencing data
Jiyuan An, John Lai, Chenwei Wang, Gregor
Tevz, Melanie L Lehman and Colleen C
Nelson
Australian Prostate Cancer Research Centre –
Queensland, Institute of Health and
Biomedical Innovation, Queensland University
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Translational Research Institute, Brisbane,
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Background: Next generation sequencing
data is increasingly common in biological
projects. Visualizing RNAseq data has
become important in the analysis of
sequencing data. IGV is the most widely
used RNA-seq visualization tool, but it can-
not simultaneously fully display other types
of custom tracks that were introduced by
the UCSC genome browser. This function
is important because it enables researchers
to simultaneously visualize gene expression
at a particular locus from multiple experi-
ments. Our visualization tool (RNASeq-
Browser) presenting here offers a user-
friendly interface for biologists.
Results: RNASeqBrowser shows the read
coverage, SNPs, InDels and raw read
tracks with other BED and wiggle tracks.
For paired RNA-seq data, paired reads are
connected in raw read track, which makes
users to identify novel exon/intron borders
and chimaeric transcripts easier. Strand
specific RNAseq data is also supported by
RNASeqBrowser that displays reads above
(positive strand transcript) or below (nega-
tive strand transcripts) a central line.
Conclusions: RNASeqBrowser can be
considered as an extension of UCSC gen-
ome browser: (i) Adding several new types
of tracks to show NGS data (such as indi-
vidual raw reads, SNPs and InDels). (ii)
Adding dynamic generation of RNA sec-
ondary structure, which is useful for iden-
tifying non-coding RNA such as miRNA.
(iii) Adding overlaying NGS wiggle data,
which is helpful in displaying differential
expression and is simple to implement in
RNASeqBrowser. (iv) In raw read track,
collapsing exact duplicate reads to reduce
visualization space reduces multi-window
display delays even in “normal PCs”. (v)
User has an option to show raw read
tracks in popup windows, which provide
users with more viewing space.
RNASeqBrowser and its manual are
freely available at http://www.australian-
prostatecentre.org/research/software/
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rnaseqbrowser or http://sourceforge.net/
projects/rnaseqbrowser/
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Objective: Androgen deprivation and
androgen targeted therapies (ATT) are
established treatments for prostate cancer
(PCa). Although initially effective, ATT
induces an adaptive response that leads to
treatment resistance. Increased expression
of relaxin-2 (RLN2) is an important alter-
ation in the adaptive response. RLN2 has a
well described role in PCa cell proliferation,
adhesion and tumour growth. The objec-
tives of this study were to develop cell mod-
els for studies of RLN2 signalling and to
implement in vitro assays for evaluating the
therapeutic properties of the unique RLN2
receptor (RXFP1) antagonist.
Methods: To validate the increased
expression of RLN2 after the ATT we
treated LNCaP cells with antiandrogens
and used qPCR to determine its expres-
sion. We established doxycycline inducible
RLN2 and RXFP1 knock-down (KD) and
over-expression (OE) LNCaP models. We
chemically synthesised RXFP1 antagonist
and evaluated its therapeutic properties in
cell proliferation and adhesion assays. To
identify paracrine action of relaxin, we co-
cultured inducible RLN2 KD and OE
LNCaP models on bioengineered osteo-
blast matrices.
Results: We confirmed the increased
expression of RLN2 after ATT in LNCaP
cells. We established and validated induc-
ible RLN2 and RXFP1 KD and OE LNCaP
models. We showed that the KD of RLN2
and RXFP1 inhibited proliferation and
adhesion of LNCaP cells. Our unique
RXFP1 antagonist inhibited proliferation
of LNCaP cells.
Conclusions: Our results show that the
inhibition of relaxin signalling supressed
proliferation and adhesion of PCa cells.
Further confirmation of these findings in a
preclinical model will be crucial step for
translation of the RXFP1 antagonist into
clinics.
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Characterisation of novel primary
tumour derived epithelial prostate
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Current translational and basic prostate
cancer research is limited by the number of
cell lines that truly reflect the spectrum of
disease progression, with most commonly
used cell lines being derived from meta-
static lesions. There are essentially no pros-
tate cancer cell lines derived from primary
tumours or localised disease in wide use.
Objective: The objective of this work is to
characterise novel primary tumour derived
epithelial prostate cancer cell lines.
Methods: We have established a number
of new prostate cancer cell lines derived
from radical prostatectomy tissue taken
from men with localised disease. Pathology
of the tissue revealed benign and adeno-
carcinoma phenotypes with Gleason scores
of 6–7 and patient PSA levels of 4–9 ng/
mL. Cells were characterised for lineage
markers, other prostate cancer relevant
targets, STR profiling, RNAseq analysis
and functional assays.
Results: RT-PCR and Western Blot analy-
sis of lineage markers confirmed these
cells are luminal in origin (cytokeratin/
CK8 and 18 positive), with low to no AR
expression. Most were also CK5, CK14
and p63 positive, which are basal markers,
and CD133 negative suggesting a mixed
lineage but not stem cell like. In initial
anchorage independent growth assays, no
growth/colony formation was observed,
however, cells appeared to remain viable.
This phenomenon may be attributed to
their early tumour origins. Further charac-
terisation of these lines is ongoing.
Conclusions: These results show potential
for these cell lines as model for primary/
localised disease. Development of contem-
porary cell lines, particularly from men with
localised prostate cancer, will provide a rep-
ertoire of more clinically relevant research
tools for the prostate cancer community.
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A multiple nucleotide length
polymorphism (MNLP) mediates
androgen regulation of IRX4 in
prostate cancer
Janaththani Panchadsaram, Gregor Tevz,
Nataly Stylianou, Brett Hollier, Colleen C
Nelson, Judith Clements and Jyotsna Batra
Australian Prostate Cancer Research Centre –
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Translational Research Institute, Brisbane,
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Objective: Androgens and the androgen
receptor (AR) play a crucial role in the
initiation and progression of prostate can-
cer (PCa), regulating the expression of
many PCa risk-associated genes. Iroquois
Homeobox 4 (IRX4) has been recently
identified with PCa risk and overexpressed
in PCa. We observed a down-regulation of
IRX4 expression in the cells undergoing
epithelial to mesenchymal transition, sug-
gesting its potential role in PCa progres-
sion and aim to delineate the androgen-
mediated regulation of IRX4 in PCa.
Methods: In-silico analysis to identify the
transcription factor (TF) binding sites reg-
ulating the IRX4 expression (Cistrome
Finder database), followed by sequencing
of these regions was performed. PCa cell
lines (DuCaP and LNCaP) were treated
with androgens for 48 h and IRX4 expres-
sion was determined by qRT-PCR.
Results: Binding of two crucial TFs – AR
and ERG, was observed upstream of IRX4
in the VCaP cells while there was no AR
binding in LNCaP cells at this locus, sug-
gesting differential androgen responsive-
ness of IRX4. Moreover, IRX4 was
up-regulated by androgens in DuCaP cells,
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but down-regulated in LNCaP cells.
Sequencing of the AR binding region iden-
tified a MNLP (rs38668493) where a
47 bp sequence is replaced by a novel
21 bp sequence. The DuCaP cells have an
intact AR binding site (47 bp/47 bp)
whereas the LNCaP cells have deleted AR
binding site (21 bp/21 bp) which may
explain this discrepancy.
Conclusion: The unique MNLP genotype
upstream of IRX4 appears to regulate AR
binding, and directs the androgen-medi-
ated regulation of IRX4. Functional studies
using reporter gene assay for the MNLP
genotype may provide further insights for
the regulation of IRX4 expression in PCa.
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Modulation of protease expression
in prostate cancer cells after
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McPherson, Melanie Lehman, Carson
Stephens, Brett Hollier, Colleen C Nelson and
Judith Clements
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Objective: Understanding mechanisms
associated with the emergence of castration
resistant prostate cancer cells (CRPC) after
androgen deprivation therapy (ADT) is
essential to create new therapeutic agents
to counteract this aggressive form of pros-
tate cancer (PCa). Because proteases are
involved in almost all cancer associated
mechanisms such as cell proliferation,
invasion and metastasis, we are interested
in their modulation in PCa after ADT and
their involvement in CRPC.
Method: First, we screened for protease
expression in hormone sensitive prostate
cancer cells (LNCaP) after ADT and anti-
androgen treatments using a custom PCa
microarray. Secondly, using RT-qPCR and
western-blots, we confirmed the deregula-
tion of several proteases which are
repressed by androgen but induced after
ADT. Finally, we analysed their expression
in C4-2B cells, which are LNCaP derived
CRPC, and in Oncomine databases.
Results: We identified several proteases
overexpressed in LNCaP cells after ADT
which are already proposed as involved in
the aggressiveness of PCa or other cancers:
BMP1, TLL1 and TLL2, three proteases of
the astacin family; MMP16, a membrane
bound MMP; and KLK14, a protease of
the same family as PSA. We also showed
that several of these proteases are over-
expressed in C4-2B cells compared to
LNCaP cells and in Oncomine databases.
Conclusion: Androgen deprivation and
androgen targeted therapies in PCa is con-
ducive to the deregulation of protease gene
expression with the overexpression of sev-
eral proteases known to be associated with
aggressiveness of PCa or other cancers. In
vitro and in vivo confirmation of their role
in the androgen deprived environment as
seen with ADT will determine their poten-
tial utilisation as therapeutic targets for
CRPC.
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Extracellular vesicles mediate
paracrine signalling in androgen
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The androgen receptor (AR) is the main
therapeutic target for advanced prostate
cancer (PCa). Current treatments have
focused on inhibiting the transcriptional
activity of the AR, however androgens can
also induce non-genomic effects by facili-
tating the initiation of kinase signaling
cascades in PCa. Cells, including PCa,
secrete extracellular vesicles (EV), which
are able to mediate communication
between cells and can also contribute
towards these processes.
Objective: We investigated the effect of
androgens and androgen deprivation in
regulating EV secretion and the role of EV
in mediating paracrine signalling in AR+
PCa cells.
Methods: PCa cells were grown in char-
coal stripped serum and treated with
androgen dihydrotestosterone (DHT) or
antagonist MDV3100 (Enzalutamide). EV
was isolated from conditioned medium
using differential ultracentrifugation
method, analysed by electron microscopy
(morphology), qNANO (size) and protein
content (LCMS/MS), followed by bioinfor-
matic (R) and pathway analysis (Ingenuity).
Data was compared with microarray tran-
scriptome wide analysis to investigate the
contribution of AR. Functional analysis by
treating androgen deprived LNCaPs with
CD9-enriched EV and the effect of knock
down CD9 on cellular growth was observed
using life imaging system Incucyte.
Results: We found that androgen depriva-
tion increases the secretion of EV in AR+
PCa cells. However, DHT increases the
secretion of CD9-enriched EV, even
though androgen treatment does not alter
the mRNA level of CD9. The CD9-
enriched EVs were able to increase the
growth rate of androgen-deprived LNCaPs,
while siCD9 reduced cell growth. Andro-
gen manipulations minimally influenced
the EV content, suggesting that androgens
alter the EV pathway(s) discrete from
genomic AR action to mediate cellular
proliferation in LNCaPs.
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Polysaccharopeptide enhanced
the anti-cancer effect of gamma-
tocotrienol through activation of
AMPK
Patrick Ling and Ji Liu
Australian Prostate Cancer Research Centre –
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of Technology, Translational Research
Institute, Brisbane, Australia
Objective: Prostate cancer (PCa) fre-
quently relapses after hormone ablation
therapy. Unfortunately, once progressed to
the castration resistant stage, the disease is
regarded as incurable as prostate tumours
are highly resistant to conventional chemo-
therapy. Therefore, an effective treatment
strategy is urgently needed for improving
the treatment outcome of the patients.
Method: We recently reported that the
two natural compounds polysaccharopep-
tide (PSP) and Gamma-tocotrienols (c-T3)
possessed potent anti-cancer activities
through targeting of CSCs. In the present
study, using both prostate cancer cell line
and xenograft models, we seek to
investigate the therapeutic potential of
combining c-T3 and PSP in the treatment
of prostate cancer.
© 2015 The Authors
BJU International © 2015 BJU International | 116, Supplement 1, 30--49 37
Translational Science 37
Result: We showed that in the presence
of PSP, c-T3 treatment induce a drastic
activation of AMP-activated protein kinase
(AMPK). This was accompanied with
inactivation of acetyl-CoA carboxylase
(ACC), as evidenced by the increased
phosphorylation levels at Ser 79. In addi-
tion, PSP treatment also sensitized cancer
cells toward c-T3-induced cytotoxicity.
Furthermore, we demonstrated for the first
time that combination of PSP and c-T3
treaments significantly reduced the growth
of prostate tumor in vivo.
Conclusion: Our results indicate that PSP
and c-T3 treaments may have synergistic
anti-cancer effect in vitro and in vivo,
which warrants further investigation as a
potential combination therapy for the
treatment of cancer.
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Objective: Kallikrein-related peptidase 4
(KLK4) is a protease with elevated produc-
tion in prostate cancer versus benign tis-
sue. KLK4 expression is associated with
prostate cancer risk, and its activity
favours tumour progression through
increasing cell motility and growth.
Importantly, over-production of KLK4 in
prostate glandular cells precedes tumour
formation, positioning the enzyme to play
a role in early remodelling of the tumour
microenvironment, a process essential for
tumour growth. We sought to identify the
proteins and downstream signalling path-
ways targeted by KLK4 activity, to define
its role in tumour microenvironment
remodelling and evaluate the efficacy of
KLK4 inhibition as a cancer therapy.
Methods: KLK4-induced gene expression
changes in prostate myofibroblasts, abun-
dant cells in the tumour microenviron-
ment, were assessed by microarray.
Complementary proteomic approaches
were employed for high-depth identifica-
tion of KLK4 targets in cell secretions.
Ingenuity Pathway Analysis software and
in vitro validation was used to determine
the resulting effect on cell function.
Results: KLK4 induced extensive gene
expression changes in prostate myofibro-
blasts, through activation of transforming
growth factor beta 1 (TGFb1) and prote-
ase activated receptor-1 (PAR-1) signal-
ling. Forty-five novel KLK4 substrates
were also identified, some of which regu-
late the activity of TGFb1, a key factor in
tumour microenvironment remodelling.
KLK4 has before been shown to activate
PAR-1 on prostate myofibroblasts, and
herein we showed this to induce expres-
sion of fibroblast growth factor-1 and -5.
Conclusions: KLK4 appears to initiate
microenvironment remodelling via proteo-
lytic activation of TGFb1 and PAR-1 sig-
nalling. KLK4 is a promising target for
inhibition as cancer therapy.
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Objective: In castrate-resistant prostate
cancer (CRPC), the prevailing organ for
metastasis is bone, where the survival of
cancer cells is regulated by the permissive
metastatic niche offered by the bone mar-
row. The tumour microenvironment and
cellular interactions with the matrix and
bone cells enable metastasis and lead to
cancer cells becoming androgen resistant.
Hence, 3D models that mimic CRPC in
terms of an androgen deprivation state
(ADS) are needed to identify the mecha-
nisms for CPRC growth in bone and fur-
ther develop therapeutic strategies.
Methods: A humanised 3D bone model
was engineered from melt electrospun
fibres and seeded with patient-derived
osteoblastic cells. The construct was osteo-
genically differentiated over 8 weeks in
culture. Prostate cancer cells, such as
LNCaP, C4-2B and PC3 were seeded
(3 9 105/cm2) on the construct and co-
cultured in FBS or CSS – representative of
ADS in vivo.
Results: The bone construct exhibited a
dense extracellular matrix (SEM, immuno-
histochemistry). Constructs were viable up
to 21 days and a mixed population com-
posed of osteoblasts and osteocytes was
observed. When seeded on the bone con-
structs, cancer cells were shown to colonise
the neo-bone matrix with LNCaP cells cul-
tured in CSS displaying a more mesenchy-
mal morphology. The expression of
alkaline phosphatase in media was signifi-
cantly altered from day 7 to day 21 and
differences in the expression of bone and
cancer genes were observed by qRT-PCR.
Conclusions: This model has proven to
replicate CRPC in vitro and will be useful
to assess the relevance of standard treat-
ments and unravel new treatment
approaches for CRPC.
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MSH2 translocations are associated
with clinically aggressive prostate
cancer
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Background: Chromosomal translocations
between distinct gene loci are now recog-
nized as a molecular hallmark of prostate
cancer. More than 50% of all primary pros-
tate cancers harbour an androgen induced
TMPRSS2-ERG gene fusion. Recently, it
has been noted that advanced prostate can-
cers have genomic re-arrangements that
disrupt the DNA mismatch repair gene
MSH2. To date it is unknown whether
translocations in MSH2 occur via the same
mechanism as TMPRSS2 and if they are
androgen induced.
38 © 2015 The Authors
BJU International © 2015 BJU International | 116, Supplement 1, 30--49
38 Translational Science
Aims: To investigate MSH2 loss in a
patient cohort and identify the frequency
of translocation events involving MSH2.
To use cell based assays to define the
affect of androgens on the frequency of
MSH2 gene translocations.
Methods and Results: Whole genome
sequencing was conducted on a cohort of
7 prostate cancer patients, one patient
was found to have a fusion gene incorpo-
rating MSH2. Validation was conducted
on a cohort of 99 recurrent and 90 non-
recurrent prostate cancer patients to
investigate the presence of functional
MSH2 protein by immunohistochemistry
(IHC). 6 of our recurrent patients were
found to have negative staining whereas
all non-recurrent patients showed positive
staining. Multiplex ligation-dependent
probe amplification (MLPA), and a novel
PCR based targeted sequencing assay
“HEPtad” were performed on the patients
that showed no staining. A break-apart
fluorescence in situ hybridisation (FISH)
assay was then applied to identify MSH2
breaks in patient samples. We also used
this FISH assay to investigate the effect
androgens on the frequency of breaks in
the MSH2 gene for LAPC4, PC3 and
VCAP cell lines.
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Combination of inhibitors of Hsp90
chaperone activity and inhibitors of
Hsp induction for better targeting
human prostate cancer
Alexander Kabakov, Vladimir Kudryavtsev,
Anna Demidkina and Vera Mosina
Medical Radiological Research Center
(MRRC), Obninsk, Russia
Although inhibitors of the heat shock pro-
tein 90 (Hsp90) chaperone activity are
considered as promising anticancer agents,
they cause induction of cytoprotective
Hsp70 and Hsp27 in malignant cells that
may impair the beneficial effects of Hsp90
inactivation. We propose to combine
inhibitors of the Hsp90 activity with
inhibitors of the Hsp induction for better
targeting prostate tumors.
Human prostate tumor-derived PC-3,
DU-145 and LNCaP cell lines and human
normal epithelium or fibroblasts were (co-
)treated with the Hsp90 activity inhibitor
(17AAG), inhibitors of the Hsp induction
(quercetin, triptolide, NZ28) and a con-
ventional drug (docetaxel) or gamma-pho-
ton radiation (2–8 Gy).
It was found that 10–100 nM 17AAG sig-
nificantly retarded proliferation of the
prostate cancer cells. As markers of the
Hsp90 dysfunction, the specific depletion
of androgen receptor and survivin and as
well as up-regulation of Hsp70 and Hsp27
were revealed in those cell samples. Co-
treatment with 10–30 lM quercetin or 2–
4 nM triptolide, or 0.3–1 lM NZ28 pre-
vented the Hsp up-regulation in the
17AAG-treated prostate cancer cells and
sensitized them to both docetaxel and
gamma-radiation. No enhanced cytotoxic-
ity was observed in normal cells co-treated
by the same way. The achieved chemo-
and radiosensitization of prostate cancer
cells appears to be due to simultaneous
blockade of the Hsp90-dependent pro-sur-
vival pathways and 17AAG-induced up-
regulation of cytoprotective Hsps.
Combination of the Hsp90 activity inhibi-
tors and blockers of the Hsp induction
enables to selectively sensitize prostate
tumors to chemo- and radiotherapy. Such
an approach may be developed into a
therapeutic modality for prostate cancer.
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The Hsp90 inhibitor, NVP-AUY922,
produces anti-tumour activity
through inhibition of fibronectin
polymerization resulting in
cytoskeletal reorganization
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Objective: Hsp90 is overexpressed in
prostate cancer (PCa) and is responsible
for the folding, stabilization and matura-
tion of many oncoproteins implicated in
PCa progression. First-in-class Hsp90
inhibitors, such as 17-allylamino-demeth-
oxygeldanamycin (17-AAG), were ineffec-
tive in clinical trials. New synthetic
inhibitors, such as NVP-AUY922, dis-
played greater efficacy through an alterna-
tive mechanism of action. This study aims
to elucidate key pathways involved in the
differential actions of these inhibitors to
better understand the basis of their
improved efficacy.
Methods: Proteomic analysis of PCa ex-
plants treated with DMSO-control,
500 nmol/L 17-AAG, or 500 nmol/L NVP-
AUY922 was performed by 2D-DIGE fol-
lowed by mass spectrometry (n = 12). Bio-
informatics analysis performed using the
Database for Annotation Visualization and
Integrated Discovery (DAVID) were vali-
dated in the PCa cell lines LNCaP, PC3,
and 22Rv1 and in prostate tumour explants
by western blot and qPCR.
Results: Bioinformatics analysis revealed 6
pathways associated with response to
NVP-AUY922. The most enriched path-
way, cytoskeletal organisation was vali-
dated and further analysis revealed both
expression and localization of key cyto-
skeletal proteins, including fibronectin and
E-cadherin, is altered in response to NVP-
AUY922, and not vehicle or 17-AAG.
Interestingly, fibronectin protein levels
increased in the cytosol but decreased in
the nucleus and extracellular space in cells
treated with NVP-AUY922.
Conclusion: We hypothesize that reduced
levels of fibronectin in the extracellular
space and nucleus is caused by inhibition
of fibronectin polymerization which results
in reduced proliferation in PCa cell lines.
The effect of NVP-AUY922 on cytoskele-
tal organisation demonstrates a novel
molecular mechanism of action underlying
its anti-tumour activity in PCa.
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Introduction: Multiple lines of evidence
suggest that altered adipose tissue homeo-
stasis contributes to prostate cancer pro-
gression. Although a number of causal
mechanisms have been implicated, sup-
porting evidence from clinical samples is
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lacking. We wished to perform an unbi-
ased screen of transcriptional and lipido-
mic changes present in adipose tissue
associated with high-risk prostate cancer.
Methods: In 2011 we incorporated routine
adipose tissue collection into our existing
banking program, whereby fresh paired
periprostatic (anterior fat pad) and subcu-
taneous (abdominal wall) adipose tissue
was obtained from patients undergoing
prostatectomy for localized prostate can-
cer. Transcriptional changes in subcutane-
ous and periprostatic adipose tissue
associated with high (n = 24) and low
(n = 24) risk prostate cancer were deter-
mined using the Illumina HT12v4 Bead-
Chip. Differences in lipid speciation were
determined by LC/MS.
Results: To date, clinically annotated adi-
pose tissue samples have been collected on
>400 patients with a variety of risk profiles,
including post androgen deprivation ther-
apy. Principal component analysis of global
transcriptional profiles shows distinct clus-
tering of individual tissue types (SC vs PP,
high vs low), permitting the generation of a
highly accurate gene classifier (AUC >0.95)
based on as few as 5 transcripts. Significant
pathways enriched on GSEA include
Chemokine signaling (q = 0.006) and NF-
kappa B signaling pathway (q = 0.02).
Alterations in lipid speciation include sig-
nificant decreases in the concentration of
20:4 containing PC lipids.
Conclusions: Adipose tissue from patients
with high-risk prostate cancer demon-
strates distinct transcriptional and lipido-
mic profiles compared to patients with
low-risk disease. These changes are cur-
rently being orthogonally validated.
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Objective: Androgen targeted therapies
(ATT) are the most commonly used treat-
ments in prostate cancer (PCa).While
these therapies are initially effective, PCa
cells are able to activate adaptive response
pathways to survive these therapies and
progress to castration resistant PCa
(CRPC), a highly aggressive and ultimately
lethal stage of the disease. Neuroendocrine
transdifferentiation (NEtD), a process
whereby PCa cells gain neuroendocrine-
like characteristics, has been implicated in
the development of CRPC. The objective
of this study is to develop and characterise
models of therapy-induced NEtD to inves-
tigate the role of this adaptive plasticity in
the progression to CRPC.
Methods: NEtD was modelled in vitro
using LNCaP cells treated with ATTs,
including ARN509, Bicalutamide and En-
zalutamide. An LNCaP-derived model of
transient androgen receptor (AR) knock-
down using an inducible shRNA system
was also developed. Expression of neuro-
endocrine (NE) markers was assessed over
time using quantitative RT-PCR (qRT-
PCR), western blotting and FACS analysis.
The expression of NE markers was com-
pared to that of androgen regulated genes
and key drivers of additional adaptive
response pathways involved in PCa pro-
gression.
Results: Preliminary results have demon-
strated that androgen deprivation, ATTs
and AR knockdown induce varying tempo-
ral dynamics of NEtD in LNCaP cells. We
observe substantial overlap of therapy-
induced NEtD with additional adaptive
response pathways. A number of these genes
have been identified to have increased
expression in metastatic and CRPC samples.
Conclusions: As the incidence of NEtD
PCa is expected to rise rapidly through the
prolonged and sequential use of new
ATTs, there is an urgent clinical need to
identify the molecular mechanisms
involved in the development of NEtD
PCa. The development and characterisa-
tion of models of NEtD will allow for the
identification of novel biomarkers and
therapeutic targets for the clinical manage-
ment of advanced PCa.
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Objective: Recent reports provide evi-
dence that the epithelial-to-mesenchymal
transition (EMT) plays a key role in pros-
tate cancer (PCa) metastasis and therapy
resistance. We have recently identified the
cell surface receptor, Neuropilin-1 (NRP1)
to be increased during epithelial-mesen-
chymal transition (EMT) and this study
aims to determine whether the inhibition
of NRP1 will be a feasible therapeutic
strategy for blocking PCa metastasis and
therapy resistance.
Methods: qRT-PCR and western blotting
was used to determine the expression lev-
els of NRP1 in metastatic PCa cell lines.
NRP1 expression in clinical samples was
assessed using immunohistochemistry and
bioinformatic analysis of multiple indepen-
dent patient cohorts. RNAi approaches
were used to assess the functional role of
NRP1 in cell migration and invasion.
Results: NRP1 expression is elevated in
metastatic PCa cells. In vitro studies have
revealed the suppression of endogenous
NRP1 levels to significantly inhibit the
migratory and invasive behaviour of meta-
static PCa cells. Importantly, NRP1 is
increased in metastatic and therapy resis-
tant clinical PCa samples and high NRP1
levels to be associated with shorter time to
tumour relapse and shorter overall survival.
Conclusion: These results will provide the
preclinical data necessary to rationalise the
use of anti-NRP1 directed therapies for
clinical use in PCa patients. Pharmaceuti-
cal companies currently have antibody and
small molecule inhibitors under early
development as anticancer therapeutics.
This study will pave the way for larger
scale preclinical and clinical trials in the
PCa setting, with the ultimate goal of
accelerating the translation of these thera-
peutics into the clinic for PCa patients.
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prostate cancer and correlates with
poor survival
Brett Hollier, Nataly Stylianou, Lidija Jovanovic,
Chenwei Wang, Melanie L Lehman, Martin C
Sadowski, Elizabeth D Williams, Jennifer H
Gunter and Colleen C Nelson
Australian Prostate Cancer Research Centre –
Queensland, Institute of Health and
Biomedical Innovation, Queensland University
of Technology, Princess Alexandra Hospital,
Translational Research Institute Brisbane,
Australia
Objective: Despite recent recognition that
the epithelial-mesenchymal transition
(EMT) program acts in a dynamic manner
(termed Epithelial to Mesenchymal Plastic-
ity or EMP) during carcinoma metastasis,
it has largely been ignored in the discovery
and development of EMT-targeted thera-
pies. In part, this has stemmed from a lack
of preclinical models that can mimic the
full dynamic nature of EMP and the per-
ception that the EMT-reverting transition
[or mesenchymal-epithelial reverting tran-
sition; (MErT)] is a mere antithesis of
EMT. The objective of this study was to
develop the first PCa model capable of
recapitulating the dynamic nature of EMP.
Methods: The LNCaP cell line was uti-
lised to develop a reversible model of
SNAI1-mediated EMT. Transcriptional
profiling and an array of biological assays
were performed to assess the role of EMT
and MErT on phenotypes relevant to can-
cer progression.
Results: Temporal transcriptional profil-
ing of EMT-induced tumour cells during
their active reversion to an epithelial phe-
notype, revealed MErT to be enriched in
clinical samples of lethal metastatic castra-
tion resistant prostate cancer. A MErT
signature was identified to correlate with
faster prostate cancer patient relapse and
poor survival across multiple carcinoma
types. MErT is not simply the mirror
image of EMT and reveal unique tran-
scriptional subprograms operating during
MErT.
Conclusions: In this study we have identi-
fied a MErT associated with carcinoma
metastasis and poor clinical outcome, and
reveal unique transcriptional networks
activated during the reversion of EMT.
This study highlights the need to consider
the dynamic nature of EMP during the
metastatic process for the application of
potential EMT-targeted therapies into the
clinic, as inhibiting EMT (i.e. activating
MErT) may reawaken dormant dissemi-
nated cells and be detrimental to the
patient.
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Objective: Prostate cancer is the leading
cause of cancer-related deaths among
men, in particular, the fourth most
common cause of death from cancer
among Asian/Pacific men. Tumor micro-
environment contributes to the origin,
restriction, invasion and progression of
prostate cancer. Oncogenic insults induced
by gene mutation may promote or restrict
tumor progression depending on activa-
tion of cellular senescence such as Pten
loss induced p53-dependent tumor restric-
tion. ARF plays an important role in
senescence but its function in genetic con-
text of Pten loss is largely unknown. p53
mutation is frequently found in various
cancers and PTEN mutation or inactiva-
tion is found in 90% cases of prostate can-
cer. Genetic engineering mouse model
with Pten loss would allow us to explore
novel signaling and avenues for targeted
therapy.
Methods: Pten/Trp53 knockout mouse
model, cell line culture, immunofluores-
cence, immunohistochemistry were applied
for investigation.
Results: ARF expression is found in both
epithelial and stromal cells in prostate can-
cer of Pten/Trp53 null mice. ARF overex-
pression decreased cellular adhesion
through targeting extracellular matrix via
matrix metalloproteinase (MMP)7 in
human prostate cancer PC3 cells. ARF
associates with MMP7 in PC3 and DU145
cells. MMP7 expression was positively
correlated with ARF elevation in human
prostate cancer specimens.
Conclusions: Oncogenic insults may cause
damages to cellular matrix and regulate
cancer progression through changes in
microenvironment. Combined targeting of
ARF with MMP7 inhibitor would be a
novel avenue for treatment of aggressive
prostate cancer.
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Purpose: Androgen receptor splice vari-
ants (ARvs) are upregulated in response to
castration, and can activate transcription
in the absence of ligand. Recent evidence
suggests that ARv7 expression predicts
resistance to abiraterone and enzalutamide.
We were therefore interested to determine
the expression of ARv7 in localized pros-
tate cancer, and correlate this with
response to an abiraterone-containing cas-
tration regimen.
Patients and Methods: We performed an
open label Phase II neoadjuvant study of
degarelix, abiraterone, bicalutamide and
prednisolone for 24 weeks in men with
high-risk clinically localized prostate can-
cer using an optimal 2-stage design. The
primary endpoints were safety/tolerability
and pT0 response rate. ARv7 expression
was determined by immunohistochemistry
and qRT-PCR in both pre- and post
treatment tumor specimens, and correlated
with pathological response.
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Results: 17 patients were recruited to the
study. Treatment was well tolerated, with
hot flushes and fatigue being the most
commonly reported side effects, and all
patients completed six months of treat-
ment. Seven patients with asymptomatic
elevation of liver transaminases required
abiraterone dose reductions, and there
were no unexpected toxicities. 16 patients
proceeded to prostatectomy, with a pT0
response observed in one patient, and
minimal residual disease present in a fur-
ther three. ARv7 expression was uniformly
present in all pre-treatment specimens,
and neither level nor localization of
expression predicted tumor response.
AKR1C3 expression was increased in
residual tumors.
Conclusions: ARv7 expression in pri-
mary prostate cancer does not predict
response to abiraterone-based castration,
however continued androgen synthesis
pathways appear relevant in resistant
samples.
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Androgen deprivation therapy is the
mainstay of treatment for advanced pros-
tate cancer. Although castration results
in tumour regression and symptom relief
in the majority, the effects are short
lived, with most patients demonstrating
castration resistant progression within
1–3 years. Numerous molecular mecha-
nisms have been implicated in the devel-
opment of this treatment resistance,
including maintenance of intraprostatic
testosterone levels and changes in the
expression/alternative splicing of the
androgen receptor. Many of these obser-
vations however have been made in cell
lines and/or xenograft models, which do
not necessarily recapitulate the complex
microenvironment in which clinical resis-
tance develops. We have recently com-
pleted a neo-adjuvant trial of
“supercastration” (degarelix, abiraterone,
bicalutamide and prednisolone) in men
with high-risk prostate cancer for
6 months prior to prostatectomy. To
identify potential mechanisms of resis-
tance as well as possible biomarkers of
treatment response, we isolated RNA
from confirmed fresh-frozen samples of
treatment resistance/persistent tumours in
6 patients, as well as 7 hormone na€ıve
samples with a similar pre-operative risk
profile. RNA was used to construct a
RNA-Seq library using NEBNext Ultra
RNA Kit for Illumina and sequenced at
a depth of 2 9 150 on an Illumina
HiSeq using paired-end chemistry.
DeFuse and Jaffa were used to detect
gene fusions, and edgeR was used to
determine differential gene expression.
Preliminary RNA-Seq data has shown a
decrease in expression of androgen
dependent genes, has detected both novel
and already identified gene fusions, and
identified activation of the calcium
pathway and other key pathways in the
development of castration resistant
prostate cancer.
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Mitochondria control cellular energy
metabolism and apoptosis, and with ele-
vated mutation rates within mitochondrial
(mt)DNA compared to nuclear DNA, it is
likely that somatic mutations of mtDNA
would significantly impact prostate
carcinogenesis. Previous studies have
mainly focused on prostate cancer (PCa)
incidence and risk in western cultures, but
presentation of PCa and associated risk
factors throughout Africa are less well
understood.
We used paired lymphocyte and prostate
tissue samples from 88 South African men,
and deep sequenced complete genomic
mtDNA of all samples. Patients ranged in
presentation from no PCa, with or without
BPH, to aggressive PCa, and include 78
African and 10 white patients. We identi-
fied 146 somatic single nucleotide variant
(SNV) mutations among all mitochondrial
samples, 80 of which were associated with
the 39 highest risk subjects. We find that
increases in serum PSA levels, cumulative
mutation variant frequency, and somatic
SNV count, were all associated with higher
Gleason score and more aggressive PCa
prognosis. We also observed that individu-
als from the earliest and most rare ances-
tral haplotype L0 presented with more
aggressive PCa as determined by higher
average Gleason score than those of later
diverging haplotypes. While no single set
of factors appear to drive PCa progression
in all individuals we provide insight into
important risk factors for African men in
addition to PSA levels and genetic back-
ground which include specific mutations
as well as accumulated mitochondrial
mutational load.
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A tale of tails – novel approach
to immunotherapy of prostate
cancer
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Introduction: The immunosuppressive
prostate cancer microenvironment renders
most infiltrating immune cells anergic or
regulatory. We hypothesise that immuno-
therapeutic agents localised to the prostate
can eliminate tumours by breaking this
immune-tolerance, with greater efficacy
and toxicity than systemically-adminis-
tered agents. We have previously shown
that a localised form of IL-15 can activate
NK and CD8-T-cells in the presence of
prostate cancer-cells. We have now used a
similar approach to modify two immune-
checkpoint blocking antibodies (patent
pending) which have been shown
previously to exhibit anti-tumour
responses in clinical trials.
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Methods: The antibodies were conjugated
to a “tail” molecule consisting of a thiol-
reactive end region, a cationic region,
binding to negatively-charged cell mem-
branes, and a hydrophobic region entering
the cell membrane. Tailing enabled the
antibodies to adhere to cell membranes
and thus localisable when injected into
tumours.
The tailed antibodies were compared to
non-tailed counterparts in in-vitro T-cell
inhibition reversal assays, and an in-vivo
prostate tumour-challenge model in C57/
BL6 mice.
Results: The tailed antibodies were both
active in reconstituting T-cell activation as
shown by IL-2 secretion in Jurkat-cells by
upto 50% (p < 0.05, n = 5) (equivalent to
the non-modified antibodies).
Furthermore we have demonstrated in-
vivo in a TRAMP-C2 murine tumour-
challenge model that a tailed-cocktail of
antibodies and IL-15 can clear animals of
tumour in 73 days compared to a 50%
reduction with non-tailed cocktail.
Conclusion: A cocktail of “tailed” IL-15
and two immune-checkpoint blocking anti-
bodies can activate T and NK-cells in-vitro
and can clear prostate tumours in mice.
These agents are therefore promising new
immunotherapeutics for prostate cancer.
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Objectives: The Australian Prostate Can-
cer BioResource (APCB) provides a unique
quality assured facility for the collection,
storage and access to tissue to support
research into the treatment and improved
clinical management of men with prostate
cancer. The APCB manages four federated
nodes located in Brisbane, Sydney, Mel-
bourne and Adelaide.
The APCB is funded by the Prostate Can-
cer Foundation of Australia (PCFA).
Results: The APCB provides a significant
number of unique services which include:
• fresh tissue
• paraffin embedded tissue sections
• buffy coat cells, serum, plasma
• tissue microarrays
To date the APCB has collected 143,302
samples from 5,630 men (Oct 2005–March
2015) and has distributed over 7,000 sam-
ples to 50 different researcher groups on
90 occasions (since 2007).
The APCB is firmly embedded in transla-
tional prostate cancer research within Aus-
tralia and provides resources to build and
contribute Australasian cohorts in large
scale genetic, genomic and proteomic bio-
markers studies. This includes the follow-
ing research programs; PRACTICAL
Genome Wide Association Study, Irish Bi-
omarker Consortium, the Movember GAP
initiative. The APCB also provides exper-
tise and infrastructure to bank samples
from the RAVES trial.
Conclusions: The APCB has a collection
of high quality prospectively collected
prostate cancer tissue with clinical and
pathological data acquired at diagnosis
and surgery. This collection has become
an important resource for prostate cancer
research both nationally and internation-
ally.
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Treatments for castrate-resistant prostate
cancer (CRPC) continue to target andro-
gen signalling leading to prolonged andro-
gen deprivation. A major side-effect of
androgen deprivation therapy (ADT) is
development of hyperinsulinaemia which
is specifically associated with more rapid
progression, but it is not clinically
addressed. Metformin is used widely in
the treatment of diabetes and hyperinsuli-
naemia.
Objective: We hypothesized metformin,
in addition to systemic reduction to hyper-
insulinaemia, may act directly on prostate
cancer (PCa) cells and aimed to provide
rationale for its combined therapeutic use
with ADT.
Methods: Microarray was performed on
LNCaP cells 10 nM insulin, 1 nM
R1881 and Ingenuity pathway analysis
used to identify pathways upregulated by
insulin including genes associated
increased survival. Results were validated
in LNCaP and C4-2B cells by qRT-PCR
and western blot, mitochondrial respira-
tion measured using the Seahorse XF Flux
analyser and apoptosis by cleavage of Cas-
pase 3.
Results: Bcl2 (8.5-fold) and Bcl-XL
(3.1-fold) and an increase in Bad were
observed following insulin treatment.
Insulin-induced changes were validated
by qRT-PCR with upregulation of Bcl2
and Bcl-XL (3.2 and 2.1-fold, respec-
tively) and decreased expression of pro-
apoptotic genes Bim and Bax (0.5 and
0.7-fold), but 2.6-fold increase in Bad.
Androgen deprivation was associated
with a 15% reduction in maximal mito-
chondrial respiration, which was restored
with 10 nM DHT, or with 10 nM insu-
lin and correlated to resistance to doxy-
rubicin-induced apoptosis. The addition
of 5 mM metformin ameliorated the
increased respiratory capacity of insulin-
treated PCa cells.
Conclusion: Metformin counteracts insu-
lin-driven survival pathways in androgen-
deprived PCa cells which support the use
of adjuvant metformin therapy in men
receiving ADT.
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Background: Androgen deprivation (AD)
therapy induces features of metabolic syn-
drome, including elevated leptin, associ-
ated with decreased time to progression.
Leptin regulates adiposity and energy
homeostasis in metabolic organs and pro-
motes proliferation; therefore LEPR antag-
onism has therapeutic potential. We aimed
to characterise the expression and activity
of leptin receptor (LEPR) in PCa cells and
determine the effect of leptin  LEPR
antagonism on migration, invasion, growth
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and metabolism of androgen-deprived PCa
cells.
Methodology: LNCaP and C4-2B cells
were treated with leptin (0.5–50 nM) 
LEPR antagonist [1–100 nM Allo-Aca (A-
A)]. Alpha-screen of phospho-p38 and -
ERK tested leptin and A-A action. Migra-
tion/invasion assessed by transwell, wound
healing and Matrigel assays and metabolic
changes by qRT-PCR and fluorescent
microscopy.
Results: LEPR was ubiquitous in prostate
cells and signalled via P38 and ERK path-
ways antagonised by A-A. Transwell
migration increased with leptin, in C4-2B,
and LNCaP cells (vs control, p < 0.01)
which was dose-dependently blocked by
A-A (p < 0.05). Leptin (0.5 nM) increased
genes responsible for fat synthesis/ storage
(SREBF1, PPARG), desaturation (FADS2)
and cholesterol synthesis (HMGCS), but
also oxidation (PPARA). Conversely, high-
dose leptin (5/50 nM) induced oxidative
(↑PPARA, ↓ACACA) and decreased fat
and cholesterol synthesis/storage
(↓PPARG, HMGCR, FASN) genes; this
correlated with lower phospho- and neu-
tral-lipid immunofluorescence.
Conclusions: Leptin stimulated PCa cell
migration, and induced metabolic changes
consistent with increased b-oxidation; a fat
metabolising profile could fuel cell growth
and motility. Future experiments aim to
establish if leptin antagonist Allo-Aca, can
block/prevent invasion and metabolic
changes and to confirm these observations
at the substrate-level using the Seahorse
metabolic analyser.
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Objective: The receptor tyrosine kinase,
EphB4, is over-expressed in many epithe-
lial cancers, including those originating
from the prostate, and plays a significant
role in promoting cancer cell migration
and invasion, both in vitro and in vivo.
We are exploring therapeutically targeting
EphB4 in prostate cancer through pursu-
ing its regulation by post-translational
modifications.
Methods: Bioinformatics in silico model-
ling and in vitro cell growth assays have
been used to explore the importance and
function of SUMOylation, which is the
covalent attachment of the small ubiqu-
itin-like modifier protein SUMO, of
EphB4.
Results: A SUMOylation motif in the
EphB4 sequence (615VKIE618) was identi-
fied and the lysine (K) mutated to arginine
(R) to prevent SUMO attachment. Expres-
sion of this mutant EphB4 protein
(K616R) caused the loss of EphB4 (mutant
and endogenous wild type) from cancer
cells, highlighting that this post-transla-
tional modification confers stability to
EphB4. In silico modelling of the ZINC
biogenic drug-like compound library
(~643 kmol) has identified two com-
pounds predicted to bind to distinct
regions of the EphB4 SUMOylation cleft.
In vitro addition of these compounds,
individually and in combination, caused a
loss of cellular EphB4 and inhibition of
cell migration.
Conclusions: These experiments indicate
that SUMOylation may be critical to
EphB4 stability and its ability to drive
tumourigenesis. This study provides a
unique insight into a previously unknown
mechanism for regulating EphB4 and
highlights a novel avenue for the develop-
ment of anti-cancer therapies with provi-
sional clinical benefit for the large cohort
of individuals with tumours over-express-
ing EphB4.
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Carica papaya leaf juice extracts
have selective anti-proliferative
responses in prostatic disease
Carina Walpole1, Saurabh Pandey2, Peter J
Cabot2, Paul N Shaw2, Jyotsna Batra1 and
Amitha K Hewavitharana2
1Australian Prostate Cancer Research Centre-
Qld, Institute of Health and Biomedical
Innovation, Queensland University of
Technology, Brisbane, QLD, Australia
2School of Pharmacy, The University of
Queensland, Brisbane, QLD, Australia
Objective: Various in vitro studies have
indicated the cytotoxic and anti-prolifera-
tive activity of Carica papaya leaf extracts
on breast, pancreas, lung, liver, leukaemia
and haematopoietic cancer cells. The aim
of this investigation is to examine the
anti-proliferative activity of papaya leaf
juice (PLJ) extracts on prostate cancer cells
(PC-3) compared to benign prostatic
hyperplasia (BPH-1) and prostatic epithe-
lial cell lines (RWPE-1).
Methods: The anti-proliferative activity of
PLJ was examined using the CyQUANT
cell proliferation assay. Cells were treated
with whole PLJ, equivalent concentrations
of serial solvent extracts (hexane, ethyl
acetate and the remaining polar fraction)
and molecular weight cut-off fractions
(>3 kD and <3 kD MW) of PLJ.
Results: The whole PLJ (1–0.25 mg/mL)
displayed significant (p3kD and <3 kD
fractions displayed strong anti-prolifera-
tive effects on RWPE-1 and BPH-1 cells.
However, no significant effects were
observed on PC-3 cells. The polar extract
displayed significant growth inhibition of
all cells. Hexane and ethyl acetate extract
(0.1 mg/mL) selectively inhibited BPH-1
and PC-3 cells proliferation up to 65–75%
compared to their vehicle control
(p < 0.05).
Conclusion: This study has demonstrated
anti-proliferative responses to Papaya LJ
extracts. Whole PLJ extract, its size exclu-
sion fractions, and the polar extract
showed anti-proliferative effects on all
prostate cells tested. The hexane and ethyl
acetate fractions of PLJ, however, had
selective effects against cell lines of pros-
tatic disease. This suggests that the non-
polar extracts may contain one or more
phytochemical(s) of selective therapeutic
potential against prostatic diseases.
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Evaluation of prostate oedema
following permanent fiducial
marker insertion in prostate cancer
patients treated at the Townsville
Cancer Centre (TCC)
Deepti Patel and Alex Tan
Townsville Cancer Centre, Australia
Objectives: Currently, prostate patients
have three fiducial marker (FM) inserted
into the prostate gland to aid image
guided radiotherapy treatment. Immedi-
ately after insertion, a verification CT scan
(VCT) is performed to ensure correct FM
placement. The planning CT (PCT) is
delayed by one week to allow for trau-
matic oedema to subside.
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The aim of the study was to demonstrate
that prostate oedema following FM inser-
tion in prostate cancer patients is not of suf-
ficient magnitude to require a one-week
interval between insertion and planning
CT. If it could be demonstrated that the tar-
get derived from VCT was not significantly
different from the PCT, it may be possible
to use the VCT for radiotherapy planning,
improving efficiency and cost benefits.
Methods: Twenty patient datasets were
examined to determine how well the pros-
tate volume generated on VCT agreed
with PCT. Volumes were delineated by a
single radiation oncologist, blinded to
whether each scan was VCT or PCT; plan-
ning target volumes (PTV) were created
and named PTVv and PTVp accordingly.
Wilcoxon rank test was used for analysis.
Results: The planning volume generated
from VCT is not significantly different
from PCT. A median volume of 6.5% of
PTVp was outside of PTVv, taking into
account intra-observer variability in vol-
ume delineation of 5–16%, the PTVv can
be deemed adequate for clinical use.
Conclusion: Results indicate the volume
derived from VCT is clinically adequate
for radiotherapy planning, eliminating one
week delay in treatment commencement.
This also decreases inconvenience to
patients, particularly those travelling from
out of town, and increases cost benefit to
the department.
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Investigation of deregulated lipid
metabolism in advanced prostate
cancer
Martin Sadowski1, Jennifer H Gunter1, Rajesh
Gupta2, Stephen J Blanksby2 and Colleen C
Nelson1
1Australian Prostate Cancer Research Centre
– Queensland, Institute of Health and
Biomedical Innovation, Queensland University
of Technology, Princess Alexandra Hospital,
Translational Research Institute, Brisbane,
Australia
2Central Analytical Research Facility, Institute
for Future Environments, Queensland
University of Technology, Brisbane, Australia
Objectives: Androgen is the major driver
of metabolic pathways in prostate cancer
(PCa), including de novo fatty acid via its
downstream targets acetyl CoA carboxyl-
ase (ACC) and fatty acid synthase (FASN).
Overexpression of FASN underpins
tumour cell survival, aggressiveness and
adverse prognosis of PCa. Despite the
abundance of exogenous dietary fatty
acids, survival and progression of PCa
depend on enhanced de novo FA synthe-
sis, which is an energy intensive anabolic
process. Yet, the reason for this critical
dependence and its relationship with other
aspects of lipid homeostasis (uptake, trans-
port, remodelling, storage and oxidation)
is still not understood. Here we investi-
gated various segments of lipid flux in
PCa cells treated with metabolic inhibitors
or different culture conditions.
Methods: Cell growth and metabolic
activity were determined with IncuCyte
technology and Alamar Blue assay.
Expression of genes involved in lipid
metabolism was interrogated by qRT-PCR.
Changes to lipid content, fatty acid uptake
and compartmentalisation were measured
by fluorescence microscopy. Mitochondrial
respiration and FA oxidation were analy-
sed with a Seahorse XF Analyzer. Lipid
profiling was performed by mass spec-
trometry.
Results: Interference with critical meta-
bolic processes (FA synthesis, oxidation,
energy homeostasis) caused distinct
changes to FA uptake, subcellular lipid
content, utilisation as energy source and
expression of genes involved in lipid
homeostasis, providing a rationale for the
limited ability of exogenous FA to rescue
viability. Lipid profiles corroborated these
findings.
Conclusion: Our findings suggest a high
degree of plasticity and dynamics of lipid
flux in PCa cells to alterations in meta-
bolic pathways or culture conditions.
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YB-1, a key regulator of androgen
receptor signaling
Anja Rockstroh, Morgan R Pokorny, Melanie
Lehman, Chelsea Walker and Colleen C
Nelson
Australian Prostate Cancer Research Centre –
Queensland, Institute of Health and
Biomedical Innovation, Queensland University
of Technology, Princess Alexandra Hospital,
Translational Research Institute, Brisbane,
Australia
Objective: Reactivation of androgen
receptor signalling is one of the hallmarks
of prostate cancer progression to the ter-
minal castrate resistant stage. A better
understanding of mechanisms driving this
adaptive response is essential for the
development of innovative intervention
strategies that effectively delay or halt
prostate cancer progression. The Y-box
binding protein 1 (YB-1) has been found
to be closely associated with prostate can-
cer progression. By characterising its role
in the adaptive process leading to castrate
resistance, we aim to promote YB-1 as a
novel therapeutic target in advanced pros-
tate cancer.
Methods: Combining data from YB-1
knock down studies, RNA-immunoprecipi-
tation experiments and ribosome profiling
enables us to discriminate and investigate
YB-1’s functions as a transcriptional and
post-transcriptional regulator.
Results: As a stress-activated transcrip-
tional regulator and RNA-binding protein,
YB-1 can contribute to the adaptive
response that leads to castrate resistance
and cancer progression in multiple ways.
Utilizing our custom designed prostate
cancer focussed microarray, we have estab-
lished a comprehensive transcriptome wide
set of YB-1’s downstream targets and
pathways in LNCaP cells. Our data indi-
cate that YB-1 regulates a large subset of
androgen responsive genes on the tran-
scriptional and post-transcriptional level,
with YB-1 knock down exhibiting a strong
anti-androgenic effect. Most importantly,
we have identified YB-1 as a master regu-
lator of the androgen receptor, controlling
its expression at multiple levels.
Conclusions: YB-1 is a potential driver of
prostate cancer progression. By regulating
the expression of the androgen receptor
and androgen responsive genes, YB-1 can
drive an adaptive response that reactivates
androgen signalling and thus enables sur-
vival and castrate resistant proliferation of
cancer cells.
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Tracking the origins and drivers of
metastasis in prostate cancer
Christopher Hovens
The University of Melbourne, Australia
Background: Tumour heterogeneity in
primary prostate cancer is well established,
however, how subclonal tumour diversity
changes during metastasis and progression
to lethality is not well understood. To
address this we performed whole-genome
and ultra-deep targeted sequencing of pri-
mary and metastatic tumours harvested
longitudinally across seven lethal prostate
cancer patients.
Methods: To map the trajectory of subcl-
onal expansion and trace the origins of
metastatic subclones, we performed
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longitudinal and multiregion sampling
yielding 31 samples across 7 patients with
lethal prostate cancer. Samples were col-
lected from primary tumours and then
longitudinally after the emergence of dis-
tinct metastatic foci, facilitating explora-
tion of the genetic changes associated with
metastasis. Fresh samples were interro-
gated with whole-genome sequencing
(WGS), RNA sequencing, and SNP profil-
ing.
Results: By tracking genomic changes
during disease progression we determined
the precise direction of metastatic spread,
revealing one case of metastatic spread to
the surgical bed causing local recurrence,
and cross-metastatic site seeding combined
with dynamic remolding of subclonal mix-
tures in response to therapy. Analysis of
mutations associated with metastasis
revealed an enrichment of TP53 mutations
and additional sequencing of metastases
from 19 patients demonstrated that acqui-
sition of TP53 mutations is linked with
expansion of subclones with metastatic
potential which can be detected in the
blood.
Conclusions: Our results suggest that the
late acquisition of TP53 missense muta-
tions in the context of a rearranged gen-
ome may confer metastatic potential to
primary tumour subclones and that these
events may be detectable in the blood. In
addition, mutational process analysis has
revealed different microsatellite instability
signatures active only in the metastatic
phase of the disease.
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Multianalyte assay for prostate
cancer
Brad Walsh
Minomic International Ltd
Introduction: Biomarkers that can assist
clinicians and patients to proceed when
PSA and /or DRE are equivocal is still
needed. Such biomarkers should establish
both sensitivity and specificity for prostate
cancer detection in order to improve go
forward decisions to perform prostate
biopsy.
Methods: Ten US clinical sites enrolled
100 patients per arm (Normal, BPH, and
Prostate Cancer). Cohort criteria com-
prised:
Arm 1(Normal)- Males >50 years, PSA
< 2 ng/mL or < 3 ng/mL if >60: Arm 2
(BPH) Normal DRE, biopsy confirmed
BPH histopathology or clinical BPH if
PSA within normal range as per ARM 1:
Arm 3 (Prostate Cancer) at least 1 week
post biopsy, Gleason score ≥7. Subjects
were excluded for presence of other can-
cers except skin cancer, non-melanoma;
or, in Arm 1 – any recent lower urinary
tract manipulation or unavailable PSA or
DRE: Arm 2 – PIN or atypia: Arm 3 –
recent 5ARI, PCA therapy or intervention-
al therapy other than biopsy.
Biomarker levels were determined in
plasma samples using both bead and plate
based ELISA assays.
Results: A combination of three markers
were selected by biostatistical analysis. A
combined specificity of 85% with a 60%
sensitivity was achieved at differentiating
between normal and benign compared to
prostate cancer patients.
Conclusions: The MiCheckTM MIA test
demonstrates potential utility as an
adjunctive test to PSA for patients. A piv-
otal trial is planned to follow up this
study.
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Determining the evolutionary origin
of lymph node metastases in
prostate cancer
Other Stefano Mangiola1, Matthew KH
Hong2,3, Geoff Macintyre4, Clare Sloggett5,
Marek Cmero2,3,4, Natalie Kurganovs2,3,
Michael Kerger2,3, Andrew Ryan6, Anthony J
Costello2,3, Niall M Corcoran2,3 and
Christopher M Hovens2,3
1The University of Melbourne, Australia
2Division of Urology, Department of Surgery,
Royal Melbourne Hospital and University of
Melbourne, Parkville, VIC, Australia
3Epworth Prostate Centre, Epworth Hospital,
Richmond, VIC, Australia
4Department of Computing and Information
Systems, Centre for Neural Engineering,
University of Melbourne, Parkville, VIC,
Australia
5VLSCI, The University of Melbourne, Parkville,
VIC, Australia
6TissuPath Specialist Pathology, Mount
Waverley, VIC, Australia
Background: The status of tumour bear-
ing lymph nodes in advanced prostate
cancer has been controversial. A key ques-
tion is whether metastatic spread to the
regional lymph nodes is an essential step
in further distant bony metastasis or
whether it is a metastatic ‘dead end’ with
little role as a conduit for further metasta-
sis. Recent clinical studies suggest that
metastatic dissemination is a complex
process and that lymph node metastases
may not directly contribute to lethality.
While key molecular pathways playing a
role in the spread of prostate cancer to
regional lymph nodes have been investi-
gated, unknown comprehensive phyloge-
netic profiling of the origins of lymph
node metastases remains to be elucidated.
Methods: Here we used copy number var-
iation, inferred from single nuclear poly-
morphism (SNP) array data, sampled from
multiple regions in primary and lymph
node tumours from within the same
patients to model the cancer evolution in
three patients with lymph node metastases.
Result: Our results reveal that regional
lymph node metastases exhibit progressive
evolution from distinct regions in the pri-
mary tumours, with metastases originating
from tumour regions with invasive proper-
ties in the prostate rather than from low
grade, non-invasive cancer tumour cell
populations.
Conclusions: This study has improved
our knowledge on the evolution of lymph
node metastases, and represents the first
attempt of phylogeny reconstruction using
gene copy number for prostate cancer.
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Factors affecting chromosomal
translocations in prostate cancer
Patrick McCoy1, Michael Clarkson2, Anthony
Costello2, Niall Corcoran2 and Chris Hovens2
1The University of Melbourne, Australia
2Australian Prostate Cancer Research Centre
at Epworth, The University of Melbourne,
Royal Melbourne Hospital, Australia
Genome rearrangements are common in
cancers and Prostate cancer is no excep-
tion. Copy number variation, which arises
from genome instability, is a powerful
marker that correlates with Prostate cancer
recurrence and metastasis by unsupervised
hierarchical clustering.1 50% of all Prostate
cancers contain rearrangements involving
genes encoding the serine protease
TMPRSS2 and the ETS family of tran-
scription factors.2 The role of these partic-
ular rearrangements in the development
and progression of prostate cancer remains
controversial, however they are regarded
as markers of genome instability which is
synonymous with cancer. It has been dem-
onstrated that rearrangements involving
TMPRSS2 are androgen dependent,3 how-
ever little is known about the influence of
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other physiological and environmental fac-
tors on prostate cancer genome rearrange-
ments.
Here we used interphase chromosome
break-apart FISH to examine chromosome
rearrangements at the sensitive TMPRSS2
loci. Prostate cancer cell lines were treated
with a variety of physiological and envi-
ronmental compounds and the influence
that this had on genome rearrangements
was then quantitatively determined.
1. Taylor et al (2010) Cancer Cell
18:11–22.
2. Baca et al (2014) Cell 153:666–677.
3. Lin et al (2009) Cell 139:1069–1083.
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A specific expression signature
accurately predicts high grade
prostate tumours in fat but not from
adjacent benign tissues
Stefano Mangiola1, Ryan Stuchbery2,3, Geoff
Macintyre4, Chris Hovens2,3 and Niall
Corcoran2,3
1The University of Melbourne, Royal
Melbourne Hospital, Australia
2Division of Urology, Department of Surgery,
Royal Melbourne Hospital and The University
of Melbourne, Parkville, VIC, Australia
3Epworth Prostate Centre, Epworth Hospital,
Richmond, VIC, Australia
4Cancer Research UK Cambridge Institute,
University of Cambridge, Cambridge, UK
Background Rationale: The accurate esti-
mation of prostate cancer progression risk
early in the course of the disease is essen-
tial for optimal management. Risk stratifi-
cation is predominantly based upon
systematic prostate sampling at biopsy, but
undergrading of tumours is frequent,
occurring in up to 50% of Victorian men
with significant implications for their care.
It has previously been reported that the
presence of prostate cancer affects gene
transcription in associated benign prostate
acini, however it is unknown if there are
detectable differences in this field effect
between men who do not require treat-
ment (low risk disease) and those that do
(high risk disease). We were therefore
interested to determine if a transcriptional
signature exists in benign tissue that can
risk stratify men with localised prostate
cancer at the time of diagnosis.
Methods: Here, employing machine learn-
ing techniques, we compare and contrast
the ability of transcriptional markers
derived from benign prostatic tissue (prox-
imal to the tumor foci) and adipose tissue
(periprostatic and subcutaneous) to predict
the tumor grade from a total of 194
patients.
Results: Surprisingly, we show that
selected transcripts (n < 5) from both sub-
cutaneous and periprostatic adipose tissue
have a significative predictive power, using
support vector machine alone, with an
area under the curve greater than 0.90. On
the contrary, transcripts from the more
proximal prostate tissue show no significa-
tive predictive power.
Conclusions: This study provides the
foundation for a potential prognostic test
for prostate cancer and offers new insight
into the biology of high risk disease.
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Targeting adaptive nutrient
metabolism pathways as a therapy
for prostate cancer
Rae-Anne Hardie1,2, Qian Wang1,2, Nicholas
Otte1,2, Michelle Simmons1,2 and Jeff Holst1,2
1Origins of Cancer Program, Centenary
Institute, Australia
2Central Clinical School, Sydney Medical
School, The University of Sydney, Australia
Background: Prostate cancer is regulated
by androgens, and the main treatment is
anti-androgen therapy. However, after
long-term therapy, tumours adapt and
become resistant to anti-androgens, caus-
ing treatment failure. We have shown that
these adaptive changes include metabolic
alterations, such as increased expression of
amino acid transporters including the glu-
tamine transporter ASCT2. In primary
prostate cancer, expression of ASCT2 is
directly regulated by androgen receptor
signalling. However, during anti-androgen
therapy, ASCT2 levels decrease, before
rebounding again during relapse and in
metastasis. These late-stage adaptive
changes in ASCT2 expression may be
mediated by transcription factors including
the androgen receptor, or activating tran-
scription factor 4 (ATF4). ATF4 transla-
tion is regulated by amino acid (AA)
deprivation and endoplasmic reticulum
(ER) stress, and can stimulate either cyto-
protective or apoptotic responses in cancer
cells. These cytoprotective responses con-
tribute to the rebound in amino acid
transporters that occurs as the prostate
cancer adapts to therapy.
In this study, we aim to characterise the
regulation of AR and ATF4 pathways in
prostate cancer cell lines, allowing us to
target these pathways with the goal of pre-
venting tumour cell growth or inducing
cell death. We hypothesise that combina-
tion targeting of amino acid transport
together with the mechanism of adaptation
to therapy, provides a novel and attractive
therapeutic strategy.
Results: We showed that both AA stress
(glutamine deprivation or inhibitor of glu-
tamine transport Benzylserine) and ER
stress (thapsigargin and tunicamycin)
induce upregulation of ATF4 and eIF2 in
prostate cancer cell lines. MTT assays as
well as IncuCyte ZOOM live cell imaging
showed a decrease in cell proliferation and
cell confluence respectively, using combina-
tions of androgen targeted therapy, AA
stress or ER stress, with an activator of
PERK, CCT020312. The effects of these
combinations on prostate cancer cells
appears to be synergistic. Apoptosis assays
were performed via flow cytometry using
Annexin V and Propidium Iodide (PI) as
well as IncuCyte ZOOM using live (Cy-
QUANT)/dead (PI) imaging. These show
that in addition to reduced proliferation,
the combination of targeting glutamine
uptake with PERK activation of ER stress
results in apoptosis in a synergistic manner.
Significance: Further studies of these
combinations will use ex vivo tumour
explant and mouse xenograft models to
determine the utility of these strategies in
preclinical models.
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Aggressive prostate cancer
presentation within an African
setting – are bacterial pathogens
contributing to exasperated
disease course?
Pieter Hendrik Bouwman1, Elizabeth A Tindall2,
Angel Valverde1, Don A Cowan1, MS Riana
Bornman1 and Vanessa M Hayes1,2,3
1University of Pretoria, South Africa
2J. Craig Venter Institute, San Diego, USA
3University of Sydney and the Garvan Institute
of Medical Research, Australia
Objective: Global disparities in prostate
cancer (PCa) are well documented. Aus-
tralia and the United States have the high-
est incidence rates. Asian countries have
the lowest. Within the United States, inci-
dence and mortality rates are dispropor-
tionally high within African-American
men. Figures for African countries, how-
ever, are largely lacking. The objective of
this study was to establish a ‘first-of-its-
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kind’ pure African PCa study to investi-
gate clinical presentation and contributing
factors leading to global disparities.
Methods: The Southern African Prostate
Cancer Study was established in 2008. We
have used this unique resource to investi-
gate clinical presentation, epidemiological
risk factors, and associated microbial path-
ogenic contributions to PCa status within
Black South Africans from rural and urban
localities. Over 1,300 men have enrolled to
date.
Results: Compared with African-Ameri-
cans, we report significantly aggressive
PCa defined by Gleason score >7 (17%
and 36%, respectively) and PSA≥20 mg/L
(17.2% and 83.2%, respectively). Addition-
ally, we found disease aggression to be sig-
nificantly exasperated in men from rural
localities (p < 0.0001). Reporting PCa is a
major public health concern for Black
South Africans, we investigate 24 possible
contributing demographic and lifestyle
measures. We found current sexual activity
and erectile dysfunction as significant risk
factors (p < 0.0001), leading to our
hypothesis that lack of pathogenic shed-
ding may be contributing to aggressive
disease within the region. Using T-RFLP
analysis, we profile for the first time bacte-
rial communities within the prostate of
Black South African men.
Conclusion: We cannot ignore the poten-
tial role of bacterial pathogens in driving
aggressive PCa within rural Africa.
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Rethinking stromal cells contribution
in the drug screening approach of
prostate cancer
Eman Mohamed Othman Mosaad, Karen
Chambers, Judith Clements and Michael
Doran
Stem Cell Therapies Laboratory and
Australian Prostate Cancer Research Centre –
Queensland, Institute of Health and
Biomedical Innovation, Queensland University
of Technology, Translational Research
Institute, Brisbane, Australia
Objective: Prostate cancer (PCa) is the
second most common cancer worldwide,
and the most common cancer in men in
developed countries. In the primary and
metastatic PCa, stromal cell contribution
to the tumor progression, invasion and
metastasis has been reported. The lack of
an effective in vitro model system of the
complex microenvironment of the PCa,
either in the primary or metastatic site,
restricts the effective screening of novel
therapeutics. To address this deficiency we
are developing 3D in vitro model system
that uses a high throughput microwell
platform to manufacture hundreds of mic-
roaggregates formed from precise combi-
nations of PCa and stromal cells. This
model system better mimics the composite
3D cellular microenvironment found in
primary and metastatic PCa tumours, and
will ultimately enable more reliable in vitro
drug screening.
Methods: Prostate cancer cells were either
seeded in mono-culture or co-culture with
a prostate-derived stromal cell line
(WPMY-1) or bone marrow stromal cells.
Bone marrow-derived mesenchymal stro-
mal cells (MSCs) were used as a source of
different bone marrow niche cells. Micro-
aggregates were treated with docetaxcel to
determine efficacy of the drug in the pres-
ence of stromal cells and this was com-
pared to the response in mono-cultures.
Results: Prostate cancer cells cultured as
3D micro-aggregates have a higher toler-
ance to drug compared to monolayer. In a
co-culture system, PCa cells responded dif-
ferently to drug when maintained in the
presence of MSC or other stromal cells
relative to mono-cultures. Changes in stro-
mal cells signalling are hypothesized to be
a critical mediators of the PCa drug sensi-
tivity: this work is on-going.
Conclusions: In summary, our results
showed that the use of the microwell 3D
co-culture system does generate more
rational cell organization, and that this dif-
ferent morphology and stromal cell com-
position does impact on PCa cell drug
response. Through further work, we hope
to determine if this system can be used to
understand which of the factors the com-
plex stromal cells microenvironment con-
tribute to PCa metastasis and the
development chemoresistance.
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Minimally invasive surgery
employing antagonistic, inflatable
robot: evaluation of positioning
accuracy and motion dynamics
Kaspar Althoefer, Helge Wurdemann and
Agostino Stilli
Department of Informatics, Centre for
Robotics Research (CoRe), King’s College
London
Current robots used for minimally invasive
surgery are conceptually centered around
the idea of open-chain mechanisms con-
structed from a series of rigid links com-
monly connected by rotary joints.
Although this approach has proven to be
very successful, especially when consider-
ing the da-Vinci surgical system, which
has shown to be an invaluable tool for a
number of surgical procedures, including
prostatectomy. Radically departing from
the current technique, we propose an
approach that takes inspiration from biol-
ogy, specifically, the octopus which shows
remarkable manipulation capabilities
despite the absence of a skeleton. By “acti-
vating” its antagonistic muscle groups at
the same time, the octopus can achieve
multiple motion patterns as well as stiffen
their arms. The proposed robot manipula-
tion concept imitates the antagonistic
muscular composition of the octopus
using a combination of pneumatic and
tendon-based actuation. This new
approach has a number of advantages over
existing rigid-link mechanisms: the pro-
posed inflatable robots are inherently safe,
can elongate and bend around obstacles,
can be squeezed through narrow openings
and can morph their state from soft to
stiff. The new concept is particularly suited
for minimally invasive procedures.
The concept proposed here goes beyond
the state-of-the-art in the field of soft
robotics: our robot is mainly made of thin
sleeve-like components filled with air to
achieve a fully-extended state, and can be
shrunk to a considerably small size when
entirely deflated.
This paper focuses on an experimental
study exploring the robot’s ability to reach
positions in its workspace and how accu-
rately to do so. The paper also explores
the dynamic behavior of the robot when
assuming different configurations. Being
able to vary the stiffness over a wide range
allows controlling the force at the tip of
the robot manipulator. The experimental
study shows that the manipulator, indeed,
is capable to bend, to morph from entirely
inflated to completely shrunk as well as to
squeeze through narrow openings, and, at
the same time, is capable to control its
stiffness over a wide range. The results
show that the robot can be suitably con-
trolled to reach desired positions, as for
example needed to grasp tissue or carry
out tissue cutting. The applied forces can
be controlled to ensure the appropriate
tool-tissue interaction. The motion capa-
bilities of the investigated arm go beyond
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what today’s surgical robotic systems can
achieve.
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Patient-derived prostate cancer
cells for piloting of drug sensitivity
and resistance testing
Khalid Saeed1, Vesa Rahkama1, Samuli
Eldfors1, Dmitry Bychkov1, John Patrick
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Prostate cancer (Pca) is the most common
noncutaneous malignancy and the second
leading cause of cancer mortality in men.
Despite the development of new next gen-
eration anti-androgens many initial
responders develop resistance in a rela-
tively short time. Thus, novel therapies are
needed for the treatment of PCa. The aim
of this project is to develop new patient-
derived Pca models and pioneer the appli-
cation of high-throughput drug sensitivity
and resistance testing (DSRT) together
with molecular and protein expression
profiling to identify novel treatment possi-
bilities for PCa.
We have established conditionally
reprogrammed cells (CRC) from prostate
patient-derived benign and cancer tissue
as described by Liu et al. (2012). The
CRC protocol allows us to initiate and
expand cell cultures directly from the
patient for 3 months and beyond, and to
generate the needed amount of CRCs for
genomic, transcriptomic and protein
expression profiling and DSRT in 2–
3 weeks from a small piece of prostate tis-
sue. CRC protocol is based on co-culture
of freshly isolated primary cells with Rho/
Rock kinase inhibitor (Y-27632) and irra-
diated 3T3-feeder cells. We have initiated
CRCs from 7 Pca patients (6 hormone
na€ıve and 1 castration resistant Pca sam-
ple; CRPC). However, only CRPC material
gave rise to cancer CRCs. CRCs retain
their epithelial phenotype and represent
transit amplifying cells with simultaneous
expression of basal and luminal cell mark-
ers. Cancer CRCs retain chromosomal
changes typical to PCa patients. The
DSRT platform has been piloted on CRCs
with a library of 306 FDA-approved and
investigational oncology drugs for high-
throughput screens testing drugs in five
different concentrations using cell viability
as read-out (Pemovska et al., 2013). The
ultimate goal is to carry out DSRT while
the patient is undergoing treatment in the
clinic, to assess the possibility of providing
options for n-of-1 type trial, if the disease
progresses beyond current treatment
options.
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Genome Mapping – a new strategy
to detect complex prostate cancer
structural genomic rearrangements
Vanessa M. Hayes
Objective: Prostate cancer is a genetic dis-
ease driven by acquired DNA mutations.
Compared to other cancers, single nucleo-
tide mutations appear to be infrequent,
while complex structural variations (SVs)
are abundant. Impacting large genomic
regions (>1 kb in length), technical limita-
tions of next generation sequencing allows
SVs to be “inferred” rather than directly
“observed”. The aim of this study was to
establish a new genome mapping technol-
ogy to observe complex prostate cancer
genomic rearrangements.
Methods: We have established the first
BioNano Irys laboratory within Australia.
The Irys system allows for the lineariza-
tion of long strands of single molecule
labelled DNA between 100 kb to 1 Mb in
length, which are passed through
nanochannels for the direct visualisation
of large SVs within intact DNA. Images
are converted into digital representations
of the motif-specific label pattern and
assembled de novo.
Results: Genome maps have been gener-
ated for a single primary and metastatic
prostate cancer with average DNA mole-
cule lengths ranging from 200 kb (tu-
mour) to 250 kb (blood). Mapped to
1009 coverage, we achieved an average
map rate of 59% (tumour) and 70%
(blood). We found an individual genome
has roughly 800 SVs, with the number of
large insertions greater than large deletions
(ratio: 1.6:1; length: 3–500 kb). The ability
to generate de novo assemblies for com-
parative analysis had a significant impact
on the detection of large deletions, increas-
ing the detection rate by 27%.
Conclusion: We generate the first prostate
cancer genomic map.
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